Cannabinoids for the treatment of cancer

Abstract

Provided herein are treatments for cancers, such as endometrial cancers. Compositions, methods, and kits are described herein. The treatments described herein for cancers can comprise cannabinoids such as cannabidiol (CBD), cancer therapeutics, terpenes, flavonoids, or combinations thereof.

Description

CANNABINOIDS FOR THE TREATMENT OF CANCERCROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present disclosures claims priority to U. S. Application No. 63 / 713,700, filed on 30 October 2024, the contents of which is incorporated herein in its entirety.BRIEF SUMMARY

[0002] Provided herein are compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids and uses thereof. Compositions, systems, and methods provided herein leverage the composition for the treatment of diseases such as reproductive cancers. Accordingly, in one aspect, provided herein compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids for the treatment of cancer which synergize with standard of care cancer treatments

[0003] Provided herein are methods for treating an endometrial cancer in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a formulation comprising: a cannabidiol (CBD), or a salt thereof; a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; a cancer therapeutic; and an excipient, a carrier, a diluent, or any combination thereof. In some embodiments, the endometrial cancer can comprise an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof. In some embodiments, the endometrial cancer can comprise an endometrial adenocarcinoma. In some embodiments, the endometrial cancer can comprise a clear cell carcinoma. In some embodiments, the terpene or salt thereof can comprise a P-myrcene, a P-caryophyllene, an ocimene, an a-pinene, an a-humulene, a linalool, a p-cymene, a camphene, a cis-nerolidol, a terpinolene, an isopulegol, a caryophyllene oxide, a 6-limonene, a geraniol, a guaiol, a-bisabolol, a 3-carene, a P-pinene, a y-terpinene, a salt of any of these, or any combination thereof. In some embodiments, the flavonoid or the salt thereof can comprise a naringenin, a naringin, a blumeatin, a butin, an eriodictyol, a hesperetin, a hesperidin, a homoeriodictyol, an isosakuranetin, a pinocembrin, a poncirin, a sakuranetin, a sakuranin, a sterubin, a pinostrobin, a salt of any of these, or any combination thereof. In some embodiments, the cancer therapeutic can comprise a chemotherapy, an non-steroidal anti-inflammatory (NSAID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and / or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipidmetabolism targeting therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, or any combination thereof. In some embodiments, the chemotherapy can comprise a 5 -fluorouracil, a temozolamide, a 6-mercaptopurine, an azacitidine, a capecitabine, a cladribine, a clofarabine, a cytarabine, a decitabine, a floxuridine, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nelarabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine / tipiracil, a cabazitaxel, a docetaxel, a nab-paclitaxel, a paclitaxel, a vinblastine, a vincristine, a vincristine liposomal, a vinorelbine, a salt of any of these, or any combination thereof. In some embodiments, the NSAID can comprise an ibuprofen, a naproxen, a diclofenac, a celecoxib, a mefenamic acid, an etoricoxib, an indomethacin, an aspirin, a ketorolac, a diclofenac, a meloxicam, a ketorolac, an esomeprazole, a nabumetone, a indomethacin, a mefenamic acid, a piroxicam, a diclofenac, a diflunisal, a sulindac, a ketoprofen, a tolmetin, a fenoprofen, a salt of any of these, or any combination thereof. In some embodiments, the platinum analogue can comprise an eloxatin, a cisplatin, a carboplatin, an oxaliplatin, a nedaplatin, a lobaplatin, a heptaplatin, a triplatin tetranitrate, a phenathriplatin, a picoplatin, a satraplatin, a salt of any of these, or any combination thereof. In some embodiments, the tyrosine kinase inhibitor can comprise a dasatinib, an imatinib, a gefitinib, an erlotinib, a vemurafenib, a sorafenib, a ponatinib, a nilotinib, a masitinib, an axitinib, a pazopanib, a sunitinib, a salt of any of these, or any combination thereof. In some embodiments, the anthracycline can comprise an adriamycin, a caelyx, a cerubidine, a cytarabine, a daunorubicin, a doxorubicin, an epirubicin, a idarubicin, a mitoxantrone, a pharmorubicin, a valrubicin, a daunorubicin, a cytarabine, a salt of any of these, or any combination thereof. In some embodiments, the taxane can comprise a paclitaxel, a docetaxel, a cabazitaxel, a salt of any of these, or any combination thereof. In some embodiments, the mTOR and / or AKT targeting therapy can comprise a rapamycin, AZD 8055, a sirolimus, a temsirolimus, an everolimus, a ridaforolimus, a deforolimus, an apitolisib, MK-2206, a afuresertib, a KRX-0401, a Honokiol, a Torinl, a PP242, a PP30, a Ku-0063794, a WAY-600, a WYE-687, a WYE-354, an INK128, an AZD8055, an OSI-02, a salt of any of these, or any combination thereof. In some embodiments, the p53 targeting therapy can comprise a RG7112, an idasanutlin, a SAR405838, an alrizomadlin, a MK-8242, a TAS-102, a talazoparib, a APR-246, a ALT-801, a salt of any of these, or any combination thereof. In some embodiments, the PARP inhibitor can comprise an olaparib, a niraparib, a rucaparib, a talazoparib, a salt of any of these, or any combination thereof. In some embodiments, the sphingolipid metabolism targeting therapy can comprise a cytotoxic retinoid, a fenretinide(4-HPR), a sphingosine kinase inhibitor, a fenretinide, a a-galactosylceramide, an ABC294640, a SKI-II, a sonepcizumab, a FTY720, atamoxifen, a synthetic ceramide, a salt of any of these, or any combination thereof. In some embodiments, the hormone therapy can comprise a progestin, a progesterone, a salt of any of these, or any combination thereof. In some embodiments, the immunotherapy can comprise a lenvatinib, a bevacizumab, a PD-1 inhibitor, a PDL-1 inhibitor, a CTLA-4 inhibitor, a TIGIT inhibitor, a TF inhibitor, a cytokine, or any combination thereof. In some embodiments, the (a) the cannabidiol (CBD), or the salt thereof; (b) the terpene, the salt thereof, the flavonoid, the salt thereof or any combination thereof; (c) the cancer therapeutic; and (d) the excipient, the carrier, the diluent, or any combination are in the form of a pharmaceutical formulation in unit dose form. In some embodiments, the cannabidiol (CBD), or the salt thereof and optionally the terpene, the flavonoid, or both can be administered consecutively or concurrently with the cancer therapeutic. In some embodiments, the administering can be performed about: 1 time per day, 2 times per day, 3 times per day, 4 times per day, 5 times per day, or more than 5 times per day. In some embodiments, the administering can be performed for a treatment duration of about: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, or longer than 3 years. In some embodiments, the subject can be diagnosed with the endometrial cancer. In some embodiments, the diagnosis can comprise a physical exam, a medial imagining exam, a biopsy, a blood test, or any combination thereof. Further provided herein are pharmaceutical compositions in unit dose form comprising an effective amount of: a cannabidiol (CBD), or a salt thereof; a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; a cancer therapeutic; and an excipient, a carrier, a diluent, or any combination thereof. Further provided herein are kits comprising the pharmaceutical compositions described herein and a container.

[0004] Provided herein are methods for treating a reproductive cancer in a subject in need thereof comprising administering to the subject a composition comprising: (a) a cannabidiol (CBD) or a salt thereof, wherein the CBD or the salt thereof activates a CBD receptor associated to the reproductive cancer in the subject; (b) a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; (c) a cancer therapeutic; and (d) an excipient, a carrier, a diluent, or any combination thereof, wherein the administering of the compositions results in the modulation of cancer-associated cell signaling in the subject. In some embodiments, the administering of the composition produces improved cancer reduction compared to a standard of care treatment for reproductive cancer without administration of the composition. In some embodiments, the modulation of cancer-associated cell signaling comprises the modulation of immunoexpression. In some embodiments, the reproductive cancer is an endometrial cancer, a uterine cancer, a vaginalcancer, a vulvar cancer, an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a soft tissue sarcoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, vascular cancer, or any combination thereof. In some embodiments, the administering comprises nonparenteral administration or parenteral administration. In some embodiments, the administering of the compositions results in the modulation of cancer-associated cell signaling in the reproductive organs. In some embodiments, the administering of the compositions results in the modulation of cancer-associated cell signaling in the lymphatic pathways and / or lymph nodes. In some embodiments, the compositions is coadministered with at least one more therapy. In some embodiments, the at least one more therapy comprises a cancer therapy, a chemotherapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, an immune therapy, a non-steroidal anti-inflammatory (NS AID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and / or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, a cannabinoid, or any combination thereof. In some embodiments, the at least one more therapy targets peroxisome proliferator-activated receptor alpha (PPARa). In some embodiments, the at least one more therapy does not comprise a cannabinoid. In some embodiments, the composition is administered in an amount of about 0.0001 g to about 500 g. In some embodiments, the composition is administered in an amount of about 1 mg to about 5000 mg of an active ingredient in a single dose. In some embodiments, the at least one more therapy is administered in an amount of about 0.0001 g to about 500 g. In some embodiments, the at least one more therapy is administered in an amount of about 1 mg to about 5000 mg of an active ingredient in a single dose. In some embodiments, the method further comprises a physical exam, a medial imagining exam, a biopsy, a blood test, or any standard diagnostic technique. Further provided herein are pharmaceutical compositions in unit dose form comprising an effective amount of: a cannabidiol (CBD), or a salt thereof; a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; a cancer therapeutic; and an excipient, a carrier, a diluent, or any combination thereof. Further provided herein are kits comprising the pharmaceutical compositions described herein and a container.BRIEF DESCRIPTION OF THE DRAWINGS

[0005] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0006] FIG. 1 shows details from sample 1. The histological analysis shows clear cell carcinoma histological grade: FIGO 3 endometrial adenocarcinoma. The immunohistological analysis shows low immunoexpression and nuclear and cytoplasmic localization of the CBD receptor. Additionally, there was low intensity expression of the CBD receptor in stromal cell and muscular cells.

[0007] FIG. 2 shows details from sample 2. Histological analysis shows endometrioid type FIGO grade 1 and 90% invasion. The immunohistological analysis shows medium immunoexpression and glandular tissue localization of the CBD receptor. The analysis also shows cytoplasmic expression of the CBD receptor in glandular cells.

[0008] FIG. 3A - FIG. 3B shows details from sample 3. The histological analysis shows endometrial adenocarcinoma endometrioid type FIGO grade 1. The immunohistological analysis shows high immunoexpression in glandular tissue of the CBD receptor. Additionally, nuclear localization (e.g., intense nuclear localization), and medium high localization was identified for the CBD receptor.

[0009] FIG. 4A - FIG. 4F shows details from sample 4. The histological analysis shows endometrial endometrioid adenocarcinoma histological grade: high grade 3. The immunohistological analysis shows intense immunoexpression and nuclear localization within lymphocytes of the CBD receptor. The immunohistological analysis shows medium immunoexpression of the CBD receptor in muscular cells and cytoplasm localization. Additionally, the immunohistological analysis of epithelial glandular cells shows medium immunoexpression of the CBD receptor.

[0010] FIG. 5A - FIG. 5B shows details from sample 5. The histological analysis shows endometrioid adenocarcinoma histological grade: FIGO 1. The immunohistological analysis shows high immunoexpression of the CBD receptor in lymphocytes and medium cytoplasmic immunoexpression in epithelial glandular cells. The immunohistological analysis shows slight immunoexpression (or negative) of the CBD receptor in connective tissue. Also, the analysis shows some high immunoexpression of the CBD receptor with nuclear localization in lymphocytes and medium immunoexpression in muscular cells.

[0011] FIG. 6 shows details from sample 6. The histological analysis shows endometrioid adenocarcinoma histological grade 1. The immunohistological analysis shows medium to high immunoexpression of the CBD receptor in cytoplasm of epithelial glandular cells and high immunoexpression of the CBD receptor in the nuclear and perinuclear regions.

[0012] FIG. 7 shows details from sample 7. The histological analysis shows serous adenocarcinoma histological grade 3. The immunohistological analysis shows mediumimmunoexpression in cytoplasm of epithelial glandular cells and medium immunoexpression in cytoplasm of muscular cells of the CBD receptor.

[0013] FIG. 8A - FIG. 8C shows details from sample 8. The histological analysis shows endometrial adenocarcinoma mitosis. The immunohistological analysis shows medium immunoexpression of the CBD receptor in the cytoplasm of glandular epithelial cells. Additionally, the immunohistological analysis shows strong immunoexpression of the CBD receptor in a few stromal cells, and low immunoexpression of the CBD receptor in cytoplasm of glandular epithelial cells.

[0014] FIG. 9A - FIG. 9C shows details from sample 9. The histological analysis shows endometrial adenocarcinoma grade 1. The immunohistological analysis shows high immunoexpression of the CBD receptor in epithelial cells and nuclear and / or cytoplasm immunoexpression of the CBD receptor in glandular epithelial cells. Additionally, the immunohistological analysis shows negative immunoexpression of the CBD receptor in stromal cells and slight immunoexpression of the CBD receptor in muscular cells.

[0015] FIG. 10A - FIG. 10C shows details from sample 10. The histological analysis shows endometrial adenocarcinoma grade 1. The immunohistological analysis shows medium / low immunoexpression of the CBD receptor in epithelial glandular cells and negative immunoexpression of the CBD receptor in perimetrium. Additionally, the immunohistological analysis shows slight (low) immunoexpression of the CBD receptor in the myometrium lining and slight (low) cytoplasmic immunoexpression of the CBD receptor in epithelium cells.

[0016] FIG. 11 shows details percent area stain for each sample in the immunostaining assay directed to PPARa receptors in uterine cancer tissue. The percent area of staining was determined for each sample as it relates to FIGO grade.

[0017] FIG. 12 shows the FIGO grade 3 uterine cancers are associated with a higher percent area stain than FIGO grade 1 uterine cancers.DETAILED DESCRIPTIONOverview

[0018] Provided herein are compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids of for the treatment of reproductive cancers. In some embodiments, reproductive cancer is endometrial cancer, uterine cancer, an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof. In some embodiments the reproductive cancer spreads through lymphaticpathways. In some embodiments the lymphatic pathways comprise lymph nodes. In some embodiments, the compositions, methods, and systems provided herein are administered via nonparenteral or parenteral administration, reaching the reproductive organs and / or lymph nodes. In some embodiments the compositions, methods, and systems provided herein synergize with standard of care cancer treatments.

[0019] In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches the cells comprising cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches CBD receptors in the cells comprising cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids modulates cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids modulates immunoexpression after administration as described herein.

[0020] In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches the cells as described herein. In some embodiments, the compositions described herein activate cannabinoid receptors in cells associated with reproductive cancers, such as for example, connective tissue cells, muscle cells, muscular cells, reproductive tissue cells, endometrium cells, epithelium cells, myometrium cells, lining cells, endometrial cells, uterine cells, ovarian cells, small cells, clear cells, stromal cells, glandular cells, lymphocytes, epithelial cells, glandular epithelial cells, epithelial glandular cells, or combinations thereof.

[0021] In some embodiments, the present disclosure relates to therapeutics, such as cannabis-based therapeutics with or without other compounds herein in the treatment of endometrial cancer. Cancer of the uterine corpus is a common gynecological cancer affecting women in the United States and is the third most common cancer affecting women throughout the world. Therapeutics are used in the treatment of adenocarcinoma of the endometrium, such as progestins. The treatment described herein (e.g., treatment with cannabinoids, terpenes, and / or flavonoids) can be used to treat endometrial cancer and / or other solid tumors with or without additional therapeutics.

[0022] In some embodiments, the compositions described herein are co-administered with at least one more therapy. In some embodiments, the at least one more therapy as described herein targets peroxisome proliferator-activated receptor alpha (PPARa) in cells associated with reproductive cancers, such as for example, connective tissue cells, muscle cells, muscular cells, reproductivetissue cells, endometrium cells, epithelium cells, myometrium cells, lining cells, endometrial cells, uterine cells, ovarian cells, small cells, clear cells, stromal cells, glandular cells, lymphocytes, epithelial cells, glandular epithelial cells, epithelial glandular cells, or combinations thereof.Definitions

[0023] Throughout this application, various aspects may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically provided all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically provided subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0024] As used herein, the term “about” a number can refer to that number plus or minus 10% or plus or minus 5% of that number. The term “about” a range can refer to that range minus 10% of its lowest value and plus 10% of its greatest value. The term “about” a range can refer to that range minus 5% of its lowest value and plus 5% of its greatest value.

[0025] As used in the specification and claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.

[0026] Unless otherwise indicated, open terms for example “contain,” “containing,” “include,” “including,” and the like mean comprising.

[0027] When used herein, a percentage of a compound (e.g., CBD or another cannabinoid) of a composition can be with respect to a total weight or a total volume of a composition. In some cases, a percentage of a component of a composition can be with respect to a total weight or a total volume of a composition.

[0028] The terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” are often used interchangeably herein to refer to forms of measurement and include determining if an element may be present or not (for example, detection). These terms may include quantitative and / or qualitative determinations. Assessing may be alternatively relative or absolute. “Detecting the presence of’ includes determining the amount of something present, as well as determining whether it may be present or absent.

[0029] The terms “subject,” “individual,” or “patient” are often used interchangeably herein. A “subject” may be a biological entity. The biological entity may be a plant, animal, or a microorganism, including, for example, a eukaryotic cell, a bacteria, a virus, a fungi, and a protozoa. The subject may be tissues, cells and their progeny of a biological entity obtained in vivo or cultured in vitro. In some cases, a subject can be a pet. A pet can be mammal, a bird, a reptile, an amphibian or any animal. For example, a pet can be a dog, a cat, a mouse, a horse, a snake, a goat, a rabbit or any animal. Non-limiting examples of mammals can include humans, non-human primates (e.g., an ape, a gibbon, a chimpanzee, an orangutan, a monkey), domestic animals (e.g., a dog, a cat, a rabbit, and a rodent), farm animals (e.g., a horse, a cow, a goat, a sheep, a pig) and experimental animals (e.g., a mouse, a rat, a rabbit, a guinea pig). A bird can comprise a parakeet, a parrot, a love bird, or any bird. A reptile can comprise a snake, a turtle, a lizard, an alligator, or any combination thereof. The subject may be a mammal. The mammal may be a human. The subject may be diagnosed or suspected of being at high risk for a disease. In some cases, the subject may not be necessarily diagnosed or suspected of being at high risk for the disease. In some cases, the subject may be healthy (e.g., the subject may not have a significant disease). In some cases, a subject can be a child or an adult. In some cases, a subject can be about 1 day of age to about 18 years of age, 1 day of age to about 120 years of age, 18 years of age to about 120 years of age, 40 years to age to about 80 years of age, or 60 years of age to about 120 years of age. In some cases, an animal can be more than about: 1 day to about 10 months old, from about 9 months to about 24 months old, from about 1 year to about 8 years old, from about 5 years to about 25 years old, from about 20 years to about 50 years old, from about 1 year old to about 130 years old or from about 30 year to about 100 years old. In some cases, an animal can be more than about: 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, or 120 years of age. In some cases, an animal can be less than about: 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120 or 130 years of age. The subject can be a patient, such as a patient being treated for a condition or a disease, such as a cancer. The subject may be in remission from a condition or a disease, such as a cancer patient. The subject may be healthy or appear to be healthy. In some instances, the subject may have a comorbidity.

[0030] The term “at least partially” may refer to a qualitative condition that exhibits a partial range or degree of a feature or characteristic of interest. For example, at least partially can comprise a partial range or degree of a feature or characteristic of interest that is at least about: 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% of the feature or characteristic.

[0031] As used herein, reference to a therapy, a compound, or a composition includes reference to any salt, solvate, ester, or polymorph of the therapy, the compound, or the composition. A “salt” can include a pharmaceutically acceptable salt.

[0032] A derivative of a compound provided herein, can refer to a chemical substance related structurally a compound provided herein. A derivative can be made from the structurally-related parent compound in one or more steps. The general physical and chemical properties of a derivative can be similar to a parent compound.

[0033] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit may be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement may be observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For a prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.

[0034] A “therapeutically effective amount” refers to an amount of a composition as provided herein with or without additional agents that is effective to achieve its intended purpose, for example to treat a disease. Individual patient needs may vary. Generally, the dosage required to provide an effective amount of the composition will vary, depending on the age, health, physical condition, sex, weight, extent of the disease of the recipient, frequency of treatment and the nature and scope of the disease or condition.

[0035] As used herein, a “dose” can refer to a measured quantity of a therapeutic agent to be taken at one time.

[0036] As used herein, the term “unit dose” or “dosage form” may be used interchangeably and may be meant to refer to pharmaceutical drug products in the form in which they are marketed for use, with a specific mixture of active ingredients and inactive components or excipients, in a particular configuration, and apportioned into a particular dose to be delivered. The term “unit dose” may also sometimes encompass non-reusable packaging. More than one unit dose may refer to distinct pharmaceutical drug products packaged together, or to a single pharmaceutical drugproduct containing multiple drugs and / or doses. Types of unit doses may vary with the route of administration for drug delivery, and the substance(s) being delivered. A solid unit dose may be the solid form of a dose of a chemical compound used as a pharmaceutically acceptable drug or medication intended for administration or consumption.

[0037] The term “substantially” or “essentially” can refer to a qualitative condition that exhibits an entire or nearly total range or degree of a feature or characteristic of interest. In some cases, substantially can refer to a total range or degree of a feature or characteristic of interest by about plus or minus: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some cases, substantially can refer to at least about: 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% of the total range or degree of a feature or characteristic of interest.

[0038] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.Compositions

[0039] The present disclosure comprises compositions comprising a cannabis, a terpene, a flavonoid, and at least one cancer therapeutic which can comprise at least one of: an antiinflammatory drug component, a progestin component, a progesterone component, a platinum analog, a tyrosine kinase inhibitor, an anthracycline, a taxane, an antimetabolite, an alkylating agent, an mTOR and / or AKT targeting agent, a sphingolipid metabolism targeting agent, an anti-VEGF agent, a p53 targeting agent, an immunotherapeutic, a PARP inhibitor, a salt of any of these, a derivative of any of these, a synthetic equivalent of any of these, or any combination thereof. Also provided herein are compositions comprising a cannabis, a terpene, a flavonoid, and at least one cancer therapeutic which can comprise at least one of: a chemotherapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, an immune therapy, or any combination thereof. In some cases, composition herein can comprise an excipient, a carrier and / or a diluent. In some cases, compositions herein can be pharmaceutical compositions in unit dose form.

[0040] Provided herein are treatments for cancer comprising a cannabis (e.g., a cannabidiol (CBD)), a terpene, a flavonoid, or any combination thereof. In some cases, treatments for cancercan comprise a cannabis (e.g., a cannabidiol (CBD)), a terpene, a flavonoid and / or at least one or more of the following compounds:1. An anti- inflammatory drug component comprising of at least one of a non-steroidal antiinflammatory drug (NSAID) that together can induce apoptosis. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any other method described herein. The compound or its components used together or sequentially can be intended for use in treating subjects that have primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.2. At least one of one of a progestin component and / or a progesterone component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any other method described herein. The compound or its components used together or sequentially can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.3. A current platinum analogue or synthetic equivalent thereof presently available or yet to be formulated drugs used as anti-neoplastic (chemotherapeutic) agents. In some cases, the compound may take the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.4. A tyrosine kinase inhibitor antineoplastic agent (e.g., dasatinib, imatinib) or synthetic equivalents presently available or yet to be formulated drugs used as anti-neoplastic or chemotherapeutic agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identifiedon a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.5. Any anthracy cline or yet to be formulated analogue or synthetic equivalent used as anti-neoplastic (chemotherapeutic) agent. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.6. Any taxane or yet to be formulated analogue or synthetic equivalent used as anti-neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.7. Any antimetabolite and pyrimidine analogue such 5 fluorouracil (5-FU) or yet to be formulated analogue or synthetic equivalent used as anti -neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.8. Any alkylating agent (e.g., temozolamide, or a salt thereof) or yet to be formulated analogue or synthetic equivalent used as anti -neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis(genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.9. Any first and second generation drugs that decrease mTOR and AKT signaling (e.g., rapamycin, AZD 8055, sirolimus, or a salt of any of these) as well as rapamycin analogues (‘rapalogs’), including temsirolimus, everolimus, ridaforolimus, or salts thereof in addition to drugs such as, but not limited to Torinl, PP242, PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, INK128, AZD8055, OSI-02, or salts thereof and yet to be formulated analogue or synthetic equivalent used as anti -neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.10. Any drug that affects the sphingolipid metabolism that enhances or increases tumor intracellular ceramide (e.g., a cytotoxic retinoid, or fenretinide(4-HPR) or yet to be formulated analogue or synthetic equivalent used as anti -neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound is intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.11. Any anti-VEGF agent (e.g., lenvatinib, bevacizumab, but not limited to these two agents) agent that enhances or increases the ability to minimize the infiltration and or progression of endometrial cancer or any anti-VEGF yet to be formulated analogue or synthetic equivalent used as a primary or secondary anti-neoplastic (chemotherapeutic) agents. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium.Cannabinoids have been demonstrated to affect VEGF function and may have a synergistic effect (in the treatment of a cancer) with an anti-VEGF agent.12. Any current agent or yet to be formulated analogue or synthetic equivalent thereof that targets the regulation of p53 and enhances or increases cell death regardless of the specific mechanism known or yet to be identified. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium. Cannabinoids have been demonstrated to affect p53 function and may have a synergistic effect (in the treatment of a cancer) with an agent that targets the regulation of p53.13. Any immunotherapeutic such as but not limited to PDL-1 and / or PD-1 inhibitors and or immunotherapeutics regardless of the specific mechanism, known or yet to be known to enhance or increase cell death regardless of the specific mechanism known or yet to be identified. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium. In some cases, cannabinoids have been demonstrated to reduce the expression of PD1-1 by both PC and PSC cells through the down regulation of PAK-1. The inhibition of PDL-1 expression by cannabinoids may enhance the anti-tumor immune response induced by immune checkpoint blockade.14. Any multi-functional enzyme Poly ADP ribose polymerase (PARP) inhibitor (e.g., olaparib, niraparib) that prevents the repair of tumor / cancer DNA damage and genome stability in patients with or without BRCA1 or BRCA 2 mutations, and regardless of the specific mechanism, known or yet to be known to enhance or increase cell death. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound may be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvantsetting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium. PARP inhibitors inhibit DNA repair pathways and cause apoptosis of cancer cells, especially in homologous recombination (HR)-deficient cells. There are reports of synergism between cannabinoids and PARP inhibitors.15. Any combination of any terpene (e.g., beta-myrcene, beta-caryophyllene) and / or any flavonoid (e.g., naringenin) that can result in apoptosis regardless of the mechanism, known or unknown. In some cases, the compound may be in the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, a suppository, or any form described herein. The compound can be intended for use in treating subjects having primary, metastatic, or recurrent adenocarcinoma of the endometrium (EAC), the most common type of cancer of the uterine corpus (CUC) or for use in the adjuvant setting, especially in those identified on a molecular basis (genetically) as being at an increased risk-of developing primary or recurrent adenocarcinoma of the endometrium. In some embodiments, a composition described herein can comprise a terpene, for example P-myrcene, P-caryophyllene, ocimene, a-pinene, a-humulene, linalool, p-cymene, camphene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, 6-limonene, geraniol, guaiol, a-bisabolol, 3-carene, P -pinene, y-terpinene, or a salt of any of these. In some embodiments, a flavanone can comprise a naringenin, a salt thereof, a naringin, a salt thereof, or any combination thereof. In some cases, a flavanone can comprise a derivative of naringenin or naringin. In some instances, a flavanone can comprise blumeatin, butin, eriodictyol, hesperetin, hesperidin, homoeriodictyol, isosakuranetin, pinocembrin, poncirin, sakuranetin, sakuranin, sterubin, pinostrobin, a salt of any of these, or any combination thereof.

[0041] In some embodiments, a composition herein can comprise a cannabinoid. In some cases, a cannabinoid can comprise a CBD and / or a THC. In some cases, a composition described herein can further comprise a monoterpene, a derivative thereof, a salt thereof, a mineral, a salt thereof, or a chelated form thereof, an amino acid, a salt thereof, a vitamin, a salt thereof, a terpene, a derivative thereof, a salt thereof, a flavonoid, a derivative thereof, a salt thereof, or any combination thereof. In some embodiments, a composition can comprise an additional therapeutic.

[0042] In some embodiments, CBD can comprise cannabidiol, cannabidiolic acid or any combination thereof. In some instances, CBD can be comprised in a composition described herein in amounts (milligram) of more than or equal to about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg. In some instances, CBD can be comprised in a composition described herein in amounts (milligram) of less than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 2000, 3000, 4000, or 5000 mg. In some instances, CBD can be comprised in a composition described herein in amounts (milligram) from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg to about 30 mg, 10 mg to about 50 mg, 25 mg to about 40 mg, 35 mg to about 60 mg, 45 mg to about 70 mg, 40 mg to 80 mg, 75 mg to about 150 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, 75 mg to about 500 mg, 250 mg to about 1500 mg, 1000 mg to 3000 mg, or 1500 mg to about 5000 mg. In some cases, CBD can comprise an isomer. In some cases, CBD can comprise trans-CBD. In some cases, trans-CBD can comprise (+)-trans-CBD, (-)- trans-CBD, or both. In some instances, CBD can comprise an enantiomer, or a diastereomer. In some instances, CBD can comprise a racemate. In some instances, CBD can comprise trans-CBD, cis-CBD or both. In some cases, CBD can comprise (1R,6R)-CBD, (1R,6S)-CBD, (1S,6R)-CBD, (1S,6S)-CBD, or a combination thereof. In some cases, a composition can comprise a ratio (weight to weight) of trans-CBD to cis-CBD of about: 1:1 to about 1:5, 1:4 to about 1:15, 1: 10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1: 150, or about 1:100 to about 1:1000. In some cases, a composition can comprise a ratio (weight to weight) of cis-CBD to trans-CBD of about: 1:1 to about 1:5, 1:4 to about 1:15, 1:10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1:150, or about 1:100 to about 1:1000. In some instances, CBD can be a powder, a liquid, an oil, an emulsion, an aerosol, a solid or a combination thereof. In some cases, CBD can be at least partially water soluble.

[0043] In some embodiments, THC (tetrahydrocannabinol) can comprise an isoform of THC. In some instances, a composition described herein can comprise an isoform of THC (e.g. A8-THC). In some cases, a THC isoform can comprise A7-THC, A8-THC, A9-THC, A10-THC, All-THC, or A13-THC. In some cases, a composition may not comprise THC. In some cases, a composition may comprise THC. In some cases, THC can comprise tetrahydrocannabivarin. In some cases, THC can comprise tetrahydrocannabinolic acid. In some cases, a composition described herein can comprise A8-THC. In some instances, THC can be comprised in a composition described herein in amounts (milligram) of more than, or equal to about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg. In some instances, THC can be comprised in a composition described herein in amounts (milligram) of less than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 2000, 3000, 4000, or 5000 mg. In some instances, THC can be comprised in a composition described herein in amounts (milligram) from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg to about 30 mg, 10 mg to about 50 mg, 25 mg to about 40 mg, 35 mg to about 60 mg, 45 mg to about 70 mg, 40 mg to 80 mg, 75 mg to about 150 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, 75 mg to about 500 mg, 250 mg to about 1500 mg, 1000 mg to 3000 mg, or 1500 mg to about 5000 mg. In some cases, a composition may not comprise a substantial amount of A9-THC. For example, the composition may comprise less than about: 1%, 0.50%, 0.40%, 0.30%, 0.20%, 0.10%, 0.05%, 0.03%, 0.02%, 0.01%, 0.009%, 0.005%, 0.001%, or 0.0001% A9-THC. In some cases, the composition may comprise more than about: 1%, 0.50%, 0.40%, 0.30%, 0.20%, 0.10%, 0.05%, 0.01%, 0.009%, 0.005%, 0.001%, or 0.0001% A9-THC. In some cases, the composition can comprise from about: 0.0001% A9-THC to about 1.0% A9-THC, 0.0001% A9-THC to about 0.02% A9-THC, 0.001% A9-THC to about 0.02% A9-THC, 0.01% A9-THC to about 0.30% A9-THC, 0.01% A9-THC to about 0.10% A9-THC, 0.10% A9-THC to about 0.50% A9-THC, 0.1% A9-THC to about 1.0% A9-THC, or from about 0.20% A9-THC to about 0.80% A9-THC. In some cases, the percentages of THC can be with respect to a total weight or a total volume of a composition. In some instances, THC can comprise trans-THC, cis-THC or both. In some cases, THC can exist as a stereoisomer, such as, (+)-trans-THC; (-)-trans-THC; (+)-cis-THC and (-)-cis-THC. In some cases, cis-TCH can comprise, (+)-cis-THC, (-)-cis-THC, or both. In some cases, trans-THC can comprise (+)-trans-THC, (-)- trans-THC, or both. In some cases, a composition can comprise a ratio (weight to weight) of trans-THC to cis-THC of about: 1: 1 to about 1:5, 1:4 to about 1:15, 1: 10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1: 150, or about 1: 100 to about 1: 1000. In some cases, a composition can comprise a ratio (weight to weight) of cis-THC to trans-THC of about: 1:1 to about 1:5, 1:4 to about 1:15, 1: 10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1: 150, or about 1:100 to about 1:1000. THC can comprise an isomer. In some instances, THC can comprise an enantiomer, or a diastereomer. In some instances, THC can be a racemate.

[0044] In some cases, a composition can comprise a ratio (weight to weight) of THC to CBD of about: 1:1 to about 1:5, 1:4 to about 1:15, 1:10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1:150, or about 1:100 to about 1:1000. In some cases, a composition can comprise a ratio (weight to weight) of CBD to THC of about: 1: 1 to about 1:5, 1:4 to about 1:15, 1: 10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1: 150, or about 1: 100 to about 1:1000. In some cases, CBD can be mixed in a composition with A8-THC, A9-THC, A10-THC or a combination thereof. In some cases, a composition can comprise a ratio (weight to weight) of A8-THC, A9-THC, or A10-THC to CBD of about: 1:1 to about 1:5, 1:4 to about 1:15, 1: 10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1: 150, or about 1: 100 to about 1: 1000. In some cases, a composition can comprise a ratio (weight to weight) of CBD to A8-THC, A9-THC, orAlO-THC of about: 1:1 to about 1:5, 1:4 to about 1:15, 1:10 to about 1:30, 1:20 to about 1:60, 1:40 to about 1:80, 1:75 to about 1:150, or about 1:100 to about 1:1000.

[0045] In some embodiments, a composition herein can comprise a cannabinoid. In some cases, a cannabinoid can be in oil form, liquid form, or solid form. In some cases, a cannabinoid can be at least partially water soluble. In some cases, a cannabinoid may include any of the identified cannabinoids, but not limited to Tetrahydrocannabinol (THC), Tetrahydrocannabinolic acid (THCA); Cannabidiol (CBD); Cannabidiolic Acid (CBDA); Cannabinol (CBN); Cannabigerol (CBG); Cannabichromene (CBC); Cannabicyclol (CBL); Cannabivarin (CBV); Tetrahydrocannabivarin (THCV); Cannabidivarin (CBDV); Cannabichrom evarin (CBCV); Cannabigerovarin (CBGV); Cannabigerol Monomethyl Ether (CBGM); Cannabielsoin (CBE); Cannabicitran (CBT); 10-Oxo-delta-6a-tetrahydrocannabinol (OTHC); Cannabichromanon (CBCF); Cannabifuran (CBF); Cannabiglendol; Cannabiripsol; and Cannabicitran. In some cases, a cannabinoid can comprise a cannabinoid from Table 1. In some instances, a cannabinoid can comprise a phytocannabinoid. In some instances, a cannabinoid can comprise an endocannabinoid. In some instances, an endocannabinoid can comprise anandamide (arachidonoyl ethanolamide) or 2-arachidonoyl glycerol (2-AG). In some cases, a cannabinoid can be a full spectrum cannabinoid. In some cases, a cannabinoid can be a broad-spectrum cannabinoid. In some cases, a composition herein can comprise one or more cannabinoids. In some cases, a composition herein can comprise 1, 2, 3, 4, 5, 6, 7, 9, 10 or more cannabinoids.Table 1: List of exemplary cannabinoids

[0046] In some embodiments, a cannabinoid can be comprised in a composition described herein in amounts (milligram) of more than, or equal to about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg. In some instances, a cannabinoid can be comprised in a composition described herein in amounts (milligram) of less than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 mg. In some instances, a cannabinoid can be comprised in a composition described herein in amounts (milligram) from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg to about 30 mg, 10 mg to about 50 mg, 25 mg to about 40 mg, 35 mg to about 60 mg, 45 mg to about 70 mg, 40 mg to 80 mg, 75 mg to about 150 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, 75 mg to about 500 mg, 250 mg to about 1500 mg, 1000 mg to 3000 mg, or 1500 mg to about 5000 mg. In some instances, a cannabinoid can comprise an isomer. In some instances, a cannabinoid can comprise an enantiomer, or a diastereomer. In some instances, a cannabinoid can be a racemate.

[0047] In some embodiments, a composition can comprise a flavanone. In some embodiments, a flavanone can comprise a naringenin, a salt thereof, a naringin, a salt thereof, or any combination thereof. In some cases, a flavanone can comprise a derivative of naringenin or naringin. In some instances, a flavanone can comprise blumeatin, butin, eriodictyol, hesperetin, hesperidin, homoeriodictyol, isosakuranetin, pinocembrin, poncirin, sakuranetin, sakuranin, sterubin, pinostrobin or any combination thereof. In some cases, a composition herein can comprise 1, 2, 3, 4, 5, 6, 7, 9, 10 or more flavanones. In some instances, a flavanone can be in the form of an extract. For example, a flavanone can be an extract from a grapefruit, a bergamot, a sour orange, a tart cherry, a citrus fruit, a tomato, a cocoa, a Greek oregano, a water mint, a drynaria, a bean, a plant or any combination thereof. In some instances, naringenin, naringin, or a salt of any of these can be comprised in a composition described herein in amounts (milligram) of more than, or equal to about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 250, 300, 350, 400, 450, 500 or 1000 mg. In some instances, naringenin, naringin or a salt of any of these can be comprised in a composition described herein in amounts of less than about: 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 250, 300, 350, 400, 450, 500 or 1000 mg. In some instances, naringenin, naringin or a salt of any of these can be comprised in a composition described herein in amounts from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg to about 30 mg, 10 mg to about 50 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, about 75 mg to about 500 mg or about 250 mg to about 1000 mg.

[0048] In some embodiments, a composition herein can comprise a vitamin, a derivative thereof or a salt thereof. In some embodiments, a vitamin can comprise vitamin A, vitamin C, vitamin D, vitamin E, vitamin D, vitamin Bl, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12, a derivative of any of these, a salt of any of these, or any combination thereof. In some cases, vitamin C can be a salt. For example, vitamin C can comprise sodium ascorbate, calcium ascorbate, potassium ascorbate, magnesium ascorbate, zinc ascorbate, molybdenum ascorbate, chromium ascorbate, manganese ascorbate or any combination thereof. A vitamin can be fat soluble or water soluble. For example, a vitamin can be comprised in an oil or in an aqueous solution. In some cases, a vitamin can be a powder or a solid. In some cases, a composition can comprise a metabolite of a vitamin, for example, dehydroascorbic acid. In some instances, a metabolite can comprise a derivate of a vitamin or a compound provided herein. In some cases, a composition described herein can comprise a choline, a carnitine or both. In some cases, a vitamin can comprise vitamin C or a salt thereof (e.g. calcium ascorbate.) In some instances, vitamin C can be comprised in a composition described herein in amounts (milligram) of more than, or equal to about: 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or 5000 mg. In some instances, vitamin C can be comprised in a composition described herein in amounts of less than about: 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or 5000 mg. In some instances, vitamin C can be comprised in a composition described herein in amounts from about: 5 mg to about 30 mg, 10 mg to about 60 mg, 20 mg to about 100 mg, 50 mg to about 500 mg, 200 mg to about 800 mg, 300 mg to about 600 mg, 400 mg to about 1000 mg, 600 mg to about 1500 mg, 1000 mg to about 2000 mg, or about 1500 mg to about 5000 mg. In some instances, a vitamin can be comprised in a composition described herein in amounts (milligram) of more than, or equal to about: 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400,450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or 5000 mg. In some instances, a vitamin can be comprised in a composition described herein in amounts of less than about: 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or 5000 mg. In some instances, a vitamin can be comprised in a composition described herein in amounts from about: 5 mg to about 30 mg, 10 mg to about 60 mg, 20 mg to about 100 mg, 50 mg to about 500 mg, 200 mg to about 800 mg, 300 mg to about 600 mg, 400 mg to about 1000 mg, 600 mg to about 1500 mg, 1000 mg to about 2000 mg, or about 1500 mg to about 5000 mg. In some cases, a composition herein can comprise 1, 2, 3, 4, 5, 6, 7, 9, 10 or more vitamins.

[0049] In some embodiments, a composition described herein can comprise a monoterpene. In some cases, a monoterpene can comprise, for example D-limonene or a salt thereof. In some instances, a monoterpene can be comprised in a composition described herein in amounts (micrograms) of more than, or equal to about: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or 5000 micrograms (pg). In some instances, a monoterpene can be comprised in a composition described herein in amounts of less than about; 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or 5000 pg. In some instances, a monoterpene can be comprised in a composition described herein in amounts from about: 10 pg to about 200 pg, 25 pg to about 125 pg, 100 pg to about 300 pg, 50 pg to about 500 pg, 200 pg to about 800 pg, 300 pg to about 600 pg, 400 pg to about 1000 pg, 600 pg to about 1500 pg, 1000 pg to about 2000 pg, or about 1500 pg to about 5000 pg.

[0050] In some instances, a composition herein can comprise a monoterpene, a derivative thereof, a salt thereof, or any combination thereof. In some instances, a monoterpene can comprise two isoprene units and have a molecular formula CioHie. In some cases, a derivative can comprise a structurally related compound to a monoterpene, a metabolite of a monoterpene, or both. In some cases, a monoterpene can comprise myrcene, menthol, nerol, pinene, camphor, myrcene, phelladrene, terpinene, pinene, camphene, citronellol, carvacrol, thymol, citronellal, thujone, limonene, carvone, linalool or any combination thereof. In some instances, a monoterpene can exist as an enantiomer, such as a D or and L enantiomer. For example, limonene can comprise a D-enantiomer or an L-enantiomer. In some cases, a monoterpene can exist as an isomer, for example a-pinene and P-pinene.

[0051] In some embodiments, a composition herein can comprise a mineral, a salt thereof, or a chelated form thereof. In some cases, a mineral can comprise: a calcium, a phosphorus, a potassium, a sulfur, a sodium, a chloride, a magnesium, an iron, a zinc, a copper, a manganese, an iodine, a selenium, a molybdenum, a chromium, a fluoride, or any combination thereof. A chelated form of a mineral can comprise copper chelate, potassium iodine, di-magnesium malate, magnesium bisglycinate chelate, zinc bisglycinate chelate, selenium glycinate, copper bisglycinate chelate, manganese bisglycinate chelate, chromium chelate, molybdenum glycinate chelate, potassium glycinate chelate or any combination thereof. In some instances, a mineral can comprise sodium chloride.

[0052] In some embodiments, a composition described herein can comprise a terpene. In some cases, a terpene can comprise, for example, P-myrcene, P-caryophyllene, ocimene, a-pinene, a-humulene, linalool, p-cymene, camphene, cis-nerolidol, terpinolene, isopulegol, caryophyllene oxide, 6-limonene, geraniol, guaiol, a-bisabolol, 3 -carene, P -pinene, y-terpinene, or a salt of any of these. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts (micrograms) of more than, or equal to about: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or 5000 pg. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts of less than about: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or 5000 pg. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts from about: 10 pg to about 200 pg, 25 pg to about 125 pg, 100 pg to about 300 pg, 50 pg to about 500 pg, 200 pg to about 800 pg, 300 pg to about 600 pg, 400 pg to about 1000 pg, 600 pg to about 1500 pg, 1000 pg to about 2000 pg, or about 1500 pg to about 5000 pg. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts (milligrams) of more than, or equal to about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 milligrams. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts (milligrams) of less than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 milligrams. In some instances, a terpene or a salt thereof can be comprised in a composition described herein in amounts from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg toabout 30 mg, 10 mg to about 50 mg, 20 mg to about 40 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, 40 mg to about 60 mg, about 75 mg to about 90 mg or about 85 mg to about 100 mg. In some instances, a composition herein can comprise a terpene, a derivative thereof, a salt thereof, or any combination thereof. In some cases, a terpene can comprise a terpene in Table 2, a derivative thereof or a salt thereof.Table 2: List of exemplary terpenes§ 64 § Nerol § 1216 § C I OHI SO § 154.................................. '..[" 105. 4,8-Dimethyinonanol. | " 1276. "[ "(5 H I 4240. [ "172.[ 106 Diosphenol [ 1276 [ C l OH 1602 [ 168 [ Z Z1S°ZZZ. ZZZZZZZZZZZZZZJZZZZZZZ Z ZZZZZZZ0. ZZZ.108. i Carvacrol. [ 1278. Lci OI 1140. [ 150.1[ 210 allo-bavanone [ 1539 j C 15112402 236 [ ZiZZ isodZZpZZZZZZZZZZZZZZZZZZZZZZZ [[[[[J 212 s Eupatoriochromene? 1726 s; 213 I cis-Davanone1 1557 i.[ 214 * Geranyl c rot onate Cl 555 [ iZi. ZZDietZZZ*ZZZZZZZZZZZZZZIZZZZZZZ i 216 i cis-8-Acetylthio-p-menthan-3-one i 1559 [[ 4-Allyl-2.6-dimethoxyphenol i 1561 [ C l I I I 1403 [ 194Sandela. [ 1568rC16H280. 1 ”236.[23........ 7. 1 1 -Dimethylheptadecane j 1792 | C 19H40 j 268 § [’ 236. Avocadynofiiran. 5'1796. (' 1711260. [246. | § 237 § Galaxolide § 1838 § (' 1811260 § 2581244 Ambrettolide 1 1905 1 C l 6112802 252 | 1 245. Methyl 4^ydroxy^methoxy^.. | C14H18O4. 250.i( 1, l -dimethylprop-2-enyl )-benzoate §§; 246 > (E)-Benzyl cinnamate § 2023 § C l 61 11402 § 238 i 247 i trans-Pinocarvyl formate 1228 C 1 1 I I 1602 180 § 248 Hex-5-en-i -ol [[ [[[[[[[[[[[[[[[ F 820 [[[[[[ rC6H12O[[[Z! 100[[[ [249. Hex-5-en-3-ol. [ 832. [0611120. [ 100.[ 250 1 -Hexanol § 837 ( 61 I I 40 Cl 02[ 254 1 2-Heptanone [ 871.([711140 [ 1 14[255[ 2-nZtZZFFFFFFFFFFFFFFFFFFFZ TSSOZZZZZJU^^ [ • 'iZZZFI [256 3 -Heptanol. [ 877. [ c 711160. [ 1 16.[ 280 i D 3 -Carene [ 1010 { C l Oi l 16 [ 136 [ [ 281 Pheny lacetaldehyde | 1612 '''ZZ 1081180 | 120 {[ 283 i p-Cymene [ 1615 i c 101114 [ 134[ 309; cis-l.inalool oxide (furanoid) { 1072 { (' 10111802 [ 170 "iTo " " " Artemisia alcohol'...[311. Dehydrolinalool. 1073.{ C I OI I I OO. { " 152.3 12 f trans-Dihydroroseoxide § 1075 s C I 0H20O i 156 313 § 4-Nonanol § 1076 § 0911200 § 144 | [.31. ZZ Ter ZZZ lZ i^^( 315; cis-Sabinene hydrate i 1082 § 01011180i 154 316 2-Nonanol [ 1085 1 C911200 [ 144§ 327 1 b-Thujone Pl 103 § 01011160 § 152 [f z a-camZjen 222222222222222Z 11 1C)ZZZ [Z IZLI ""i ZZ 329 2 2'.5,6-Tetramethy Icyclohexanone || | 06C10H18O 154i (Isomer 2 )330 2-Vlethyl-5-propionyl furan § 1 108138 33 £Zci s-SZenth[ZZZoLZZ[^^ZI 11 1T " [c I oj MOO ZZ 1' '^ZZZ § § 4.8-Dimethylnona- l.3.7-triene;Z 1 1 Z l l H I 8 150 s 1 (Isomer 2) s ' i s '?; 334 § a-Pinene epoxide (Isomer 2) 1011160H 52 335 i trans-Rose oxide 10H18O § 154[ 336 Di h \ d rol i nal ool ZZZZZZZZZZ 1011200 " 156 [[[33. Z IRSZZZ[338 Camphor § 1 123 § 01011160 § 152 [UZ transZ^enth-2-en-i-oi [. [ | [ 0. FC16H18O' [[. ['^ZZ' 1 f'340. § (E)-Ocimenoxide. F§ 341 i p-Menth^[,5-diene-8-ol [1 127 I 10H16O [ 152[347 (Z)-Tagetone [ 1 136 iC lOH 160 § 152HO I 1 Tuberolactone § 1437 § 010111402 § 166 [fiZZi,’anZZZZ 9LZZZZZZZZZZZZZZZL''L?9ZZZZZZZJZ[ZQ’'i’Z ZZZZZ[jZZZZZ'] 463 Dihydrocarveol (Isomer 1) H 176 ( 1011180 H 54 § 464 § Dihydrocarveol (Isomer 2)§ 01011180i 154 § 465: Dihydrocarveol (Isomer 3) i 1205 i C10H18O i 154[ Zoo Zc> s-caZZZZZZZZZZZZZZ121ZZZZZZZ Z ZZZ ZZZZ § 467; 4-Methoxyphenylacetone § 1343 H I OH 1202 § 164 i 468 § 4-Methoxypropiophenone 1415 H I OH 1202 i 164[469[zGrandZoi[ zziimmzi20Zzz. [Zpizozz. r'^zz (ZZHotZZZZZZZZZZZZZZ108ZZZZZZZZZZZZZZZZIZZ § 471 Hsopinocampheol § 1 168 § C 10H 16O § 152 |472 ' < E)-Pseudoisoeugenyl-2-methyl || s,. I C15H20O3 I 248§ butyrate§ 476 § u-Hexanolide § 1006 § 06111002 § 1 14§ 483 § g-Tetradecanolide § 1866 § 014112602 § 226 ( 484 Z d -N ZZZZiZZZZZZZZZZ "T13dZiZZZZIZiZ Z Z. [13ZZ (ZZ d-OctandiZ '' [.z [ 4z87z § ddH_Dieepc~tz“^zzd^^zzzzzzzzzzzizzzzzzzz zznzzzzzzn§ "488. (E)-a-Damascorie. I’ ”1’375. F ci3H2b6. § "192.536 § b-lrone PI 566 § (' 1411220 206 537!Benzyl acetate( 1 1341 C9H10O2( 150 | L. Z. ZZZZfiZZ^^| 539 d-J asnioi act one. [ 1450. [' C 1 OH 1602 [ "168. | 540 i N-Acetyl methyl anthranilate ( 1565 ( C10H11O3N i 193 [ ZZZZZ[ 542 i 6-MethylheZ-^-en-2-one f 978 C8H 140 [ 126 ( 543 I Rosefuran 1 1091 i C. I OH MO ( 150 t 544 s Rosefuran epoxidet 1 161 1 C l OH 1402t 166 ( 545 I b-Pinene 1978 i.. I OH 16 ( 136 [’ 546. [ Myrcene. [ 987. ['(' 101116. ["136. | | 547 Oct-3-en-l-ol (Isomer 2) 1049.. 1 C8H16O _ | 128 Fs48| 343i cifflism 1 194i549 (E)-4-Propeny (phenol anuelate 1751 ( 14111602 < 216[559^ b-Thr^li [ CWHI20ZZ ^ZZZ] [ 560. n-Undecane. [ "1 100. §["c I 11124. [ 156. ( 561 n-Nonane ( 906 ( C9H20 § 128"562"""' j Pinocamphone ---------------------------------------------- -i-i-At ----- [ C1OH16Q [ ^^ZZI § 563 Isopinocamphone § 1 151 ( C10H16O § 1521609 I 1449 i C15H24O h20di hydrochi loscy phol one[ 619 lamariscol 1535 j (’1511260 222 ^ ['620. Paciligorgioi. I 'p539. P 01511260. [222.; 62l i (E, E)- ethyl 10-oxolarnesoate C1896; (’ I6H26()3 1 266[ "622. b-Caryophyllen^' oxide546.P C15H24O. [ 220.1§[62ZZ4bl< Z3[33SZZZZ. Z^ "626. Dactyiol. [ 1556. (' 1511260. [222. |: 627 §§ cis-Sesquisabinenhydrate i 1558 §§ C 15H26O § 222§ 632 § b-Himachalol § 1638 § C 151126() § 222[633. Maaiioi. [ 1565.§ 634 s Deoxopinguisone i 1563 § C I 5H22O § 2182-Methyl-l -( octahydro-7.7a- 649 § dimethyl-l I l-inden-l -yl)-propan- l - § 1601 § C15H26O § 222§ one§§ 659 § Gymnomitrone §§ 1620 §§ C 15H22O §§ 218 [ [ [ "[ 713!Farnesol (Isomer 1 ) _ [ 1694 _ [ ( 1511260 [ 222 _ 714; 6a-Hydroxygermacra- l ( 10),4-diene s 1687 ( 1511260 222. '....[Z<5 8 tran^DimeSyM^- [,350 fa2H20O Gso epoxydecaline[ 747 [ Peculiaroxide [ 1416 [ ( I 5H26O [ 2221 778 i Cyperol ( 1681 [61544240 ( 220 1787 (E. E)-Alethyl 10. 1 1 -epoxy farnesoate s 1875 t C16H26O3 s 266 | 788 " ' EudZmZllSZZlZS ^ ZZZZ1177^^ 661511220 Zl'ZZZ*) ( 789. Zizaeinic acid. ( 1791. ( "615442202. [234. (s 863 i Epicurcerenone t 1593? 015111802; 230[883 i Alantolactone [ 1873 j C 15H2662 [232 3 == 884 = Dihydroisoalantolactone 1875 == C 15H22O2 == 234[885 1|;ru||an[| ['''''''' 1906[[[[ 33[ ^■[5|'|20O2 ■■■■■■■■ 23233 [886. Isoalantolactone. 1912. 6151120 2. [232.[887 ent- iplophyllolide 1937 [015112002 [232[888 Guaia-6.9-dien-4b-o 15651 C 1511240220 I 889 I Guaia-6. I O( l4)-dien 1610 = 01511240 I 220 | 890Cedrenone1722 (' 1511226 [218LZ. ZZGGJZZ ZZZZZZZZZZZZZZ162ZZZ [959 Z I 154" Z rZIlEllIIIIZ162zzi i 960 i Trinoranastreptene 197 s C 12H 16 160 1961 l,4a-5metZl-WA4233j C l 21120 164f octahydro-naphthalenei 962 i Pregeijerene i 1288 i C l 21118 162, 963, (Z)-2,6 194idienes 964 i Isocyclobazzanene; 13 19 s C 15H24 s 204 965 i 8,9-Didehydrocycloisolongifolene? 1320? C 15H22 202 |g66(E)-2,6,10-Trimethylundeca-2,6- j| 321iC14H26 \ 194i diene i j[ 967 1 Cyprotene [ 1322 [. C.14H24 [ 192 [ [968 [[l2esiipiiip zzzzzzz i32 zzz. [ cj 51124[ 969 7^ ^.^.. zzz*. r'2ozzz] [ZzZZBraZZZZZZZZZZZZZ^ [ 971 Bicycloax-4(T5)-ene [ 1336LZ ZBicZZZZZZZZZZZZZZZZZZZZ ^^ [IzZZ d-EiZnen Z222222222222222222Z,,r,,134oZ22Z[. c[5H24ZZIZ.12C)1ZZ] ^ 974 3, 10-Dihydro-l,4-dimethyiazuiene i 1342 i C12H14 i 158 LZ ZPreZihZZZiZZZZZ Z[ 976 Pentalenene 1343 | C I 5H24 204 [ [ [ZZZZ African-5-ene. F 1350 f'c i'5H24. ^[ZZZZ [ 978 African-2(6)-ene 21350; C I 5H24 i 204[ 979 Maa,li- 1,3 -diene [ 1347 IC15H22 [ 202[990 CyperadieiZZZZoo l i Cyclomyltaylane [ 1366 [[ZZHZ””” [[[[[[20 [[[[[| i 992 i 1 -epi-a-Pinguisene 1367 s C I 5H24 i 204 993!Brasi la-5( 10 ).j ( 994 1 Anastreptene [ 1373 [ C l 51122 [ 202[995. Capnell-9(12)-ene. [ 1372.| [ 996 a-Ylangene [ 1376 1 C l 51124 | 204[ 1001 a-Bourbonene j 1378 | (’ 151124 | 204 i [ "1002. Daucene. [ 1380. [ C15H24. ['204. \ Cl 003 i Silphiperfol-6-ene 1378; C 151124; 204 [[1004[[ BourjZZZZZZZZZZZZZZZZZZ^^ 1 1005 i a-Elernene [ 1381 1 [ 1006 1 lsodauca:4.7( M)-diene [ 1381[ 1007 « Isoledene [ 1382 j [ 1008 Protoil lud -6-ei^ ['1009Longicycien^. [ 1 82.. | [ 1010 Modhephene [ 1383 [ C l 51124 | 204 |[1619 i lsodauca-4[6-diene

[1385] O 5H24 1 204[ 1028 s l[ 1390 1. C15H24 [ 204 | 1029 [[ A..[ 1030 B[ 103 r ' 1 sol ongifol ene[[[[[[[[[[[[[[[[[[[[[[[[[ 1040!7-epi-a-Cedrene 1404- C l 51124 204 |7ZZZ CasZlZZZpZZZZZZZZZZZZZ ^^[ 1057 ' ’ isos7ZZZZZZZZZ[^^. rZZB14[[[[[7. [2C)4[77 [1058Z 'i4it mZZZZZZZZZZZZZZZ[^^1[ 10627 7.1063Z[ 1064 (Z)-b-Farnesene [ 1420 [ C l 51124 [ 204 [1 1279 § Norrotundene [ 1421 [ C 14H22 [ 190 1[ 1309 s Drim-8-ene [ 1442 26 [ 206[13 T 7 sei i n7Zi7777177eZ7777777777 [146172277777 [2627771[ 1 1 15,6-Peliydroaiaskene7 7..[ "1312 (all-Z)-6[9[ili'5'lleneicosatetraene [204836. [ 288.L.1313 i.. Isoperillene [ 1073 I. C10H 14O 150 | 1314 [ (E)-(’innamyl isovalerate _ j 1641 | C 14111802 218 _ [ 1315 ( (l')-Cinnamyl isobutyrate i 1543 i C13H16O2 i 204 1316 i (E)-Cinnamyl propionate i 1500 i C12H14O2 i 190 1317 i (Z)-lsobutyl cinnamatei 1593j (’ 13111602[ 204 [.1318...''^^["l 3 19 I 7-epi-Eremophila- (10)'8' 1 1 -triene [ 1508 J C I 5I I22 [ ' ' [[[[[[[[202 [ | t 1320 i 5-Hydroxymarsupellyl acetate 1814 == C I 7H26O3 t 278 t 1321 s Marsupellyl acetate t 1681 C 17H26O2 t 262 t 1322 = 4-epi-Marsupellyl acetate 1733 C I 7H26O2 t 262 1323; (E)-Methyl p-methoxycinn 1625 C 1 1111203 [ 192 1324t (Z)-Methyl p-methoxycinn t 1543C11H12O3i 192 = 1325 1 4-epi-Marsupellol 1 1614 ^ C 15H24O = 220[ 1326 [[[ (Z)-Cinnaniyl propionate § 1552 I C 12111402 U'? Z I i 1327 i (E)-lsobutyl cinnamate t 1633 == C 13H 16O2 t 204 i 1328 i Methyl 4-methoxymandel$ 151 1$ C l OH 1204t 196[ 1329:(E)-lsoamyl cinnamate i 1697 = C 141118()2 i 218 i [ 1330. Pentadecanoic acid. [ 1823. [(515443'602. ['242. 133 1 s Methyl o-methoxybenzoate? 1300 t C9H 10O3 166 [[1332[[atEZ9 ZZZZ 11333 i Syringa aldehydei 1334 = Methyl 3-methylorsellinate t 1674 C l OH 1204 t 196[ 1335 « Di hyd roacti nidi ol ide [ 1487 [ C 11111602 [ 180 | l 336 b-lonone epoxide["1337Oxoisophorone. [' "l "l "l "l. ['(59441202. ["152.[ 1338 Sabina ketone i 1 132 1 C9I I I4O [ 138 | ] iQl lZ Cabreuvaoxide ^^1^^^^22Q [[] [ 1347. i Cabreuva oxide B. [ "1452. ['(51'544240. 220. i 1348 1 Cabreuva oxide C 1456 ^ C 15H24O = 220 1349 = (E)-o-Methoxycinnamaldehyde 1477 (' 10111002 162 t 1350 i (Z)-o-Methoxycinnamaldehyde 1408 C 10H 1002 t 162 i 1351 i Hydroci nnamyl acetate 1336= (' 1 1111402 == 178[ 1352Methyl methyl anthranilate[ 1372 L. C9H11O2N[ 165[ 1353 Abietal i 2261 | C20H300 i 286 i [ 354[[ trans-Totarol. ["2241. i "'<52044300. i [EEZZJ1358 4-(4-Hydroxyphenyl)-2-butanone i 1508 i C 10H 12O2 i 164 1359 15-Norlabdan-8-ol [ 1943 C l 911360280 j 17'1333.7()9393I 3?333333333333^[1361Z Sciar3i3133333333333333333 [2022333. F333 Q [3 [264733 1362 1 -Decanol i 1264 j C 1011220 [ 158 [[13633 Am37i377773777777777777777777L17i7777777777I73L|26(1777777I'246777j 1364 Methyl arachidonate 2217 i C21 H34O2 i 3 18 1365Cyc!.omyltaylan:15-ol [ 1641 L11 I. I24O [.220 g 1366 Tridenson § 1633 [ C 15H26O i 222.1 67Tri33337[[[[[[[[[[[[[[[[[[[[[L1317[[[[[[[J3l5H3o3[[[[[[L222[77J [ 36 6b-Acetoxyeudesm-4( 15)-en-7b-ol i 1898 i C18H30O2 i 278py rano | 4.3 -b J py ran- 5 -one'....11533 1 (E)-2-Decenal [ 1240 I. C 10H18O [ 154 1534 s 2-methylbutyl hexanoate? 1235 s C l 1142202186[ 153ZZ n-I lexylTm^jtono^^^| 1536 n-I lexyl butanoate. F l 176 [ "(’ 10112002 [ 172. | 1537 (E)-2-Heptenal [942[ (’711120 [ 1 12[ 1538 f ' I'enchy acqtate gsqm^^i "l 539 i 1 l -Nordrim-8-en-12-ai i 1609 | C 14H22O [ 206[ 1548 i n-Heptadecane [ 1700 [ C l 71136 [ 240[ 1549 I n-Octadecane j 1792 | (’ 181138 L. ZiZZZ [ "1550. n-Eicosane (C-20). f 2000. ('201142. ["282. \ [ 1551 i n-Heneicosane (C-21 ) [ 2100 | C21 H44 [ 296[[IZ?2Z (E)-Non [en[4[o^^ | 1793 ' (E)-3-MetiZZZZl^^. F^ZZ ZJ § 1794 t Isotheaspirane (Isomer 1 )194 | 1795 Isotheaspir^e (Isomer 1 ) [ 1279 I C 1311220 [ 194 | [1ZZZ •Chil?scyphone FFFFFFFFFFFFFFFFFFCJZZZFFFFFFFFFLZJZ11JZ^O FFFFF ZFZFFFFJ. 2-Hydroxy 35-dimethoxy910... I". ||| i 806 1 n-Biitd but rate ZZZZZZZZZ F^o FZZ [ C8H16QZF Z 1 •44 ZZ 1 1 1807. i n-I Iept r^tanoate''''' ' '||i 4-one[ 1931 endo-Brevicomin [ 1039 C9H16O2 1561941 Di-n-propyl tetrasulfIde 1558 C6H14S4 i 214 1942.54>entyb3A54rimethyb5H ii1ran-2 || 474. |"C12H20O2.1 196.§ one[ 1943 i..i’lagiochiHine T 1 1665 [ C 15H20O 1216!" 1944. ":Plagiochi 1945 -vlejhylc i 1946 f 3-Ethylcy1947 s Methyl 3-ethyl-4-methylpentanoate t 1021 s C9H 18O2 158[ 1948. 2,4-Diethyioct-l-ene. 1 106. 12H24.i 1949 i Methyl trans-Dihydrojasmonate t 1623 13H22O3 § 226 i 1950 s cis-Methyl dihydrojasmonate t 1651 13112203 § 226 1951 l.7-Dioxaspiro| 5.5 |undecanes 1 108 9I I I 6O2 156[ 1952 (2Z.4E)-Methyl abscisate § 2076 16112204§ 278[ 1953 (2Z,4E)-Met^l phaseate [ 2141 16H22O5 [ 294[ "1'954" [[ (2E.4i[)-Metiiyi [abf^^ 1OT22Q [Z.[ 1955. Pityol. 19458H§1602. §§ 1 4. 1 1956 6-Ethyl-2-methyl-2,3-dihydro-4H- || 1 | 7j C8H12O2 1 140 § § pyran-2-one § §§[ "1957. [ n-Nonyi acetate. F l §283. [ "C1 U422O2. [ "186.1

[0053] In some embodiments, a composition herein can comprise an oil. In some cases, an oil can be an oil of a plant, an animal, or both. In some instances, an oil can be an essential oil. An essential oil can be a plant extract. In some cases, an oil can be a cooking oil. In some cases, an oil can comprise an avocado oil, a soybean oil, a black currant oil, a lemon grass oil, a peppermint oil, a lavender oil, a sandalwood oil, a bergamot oil, a rose oil, a chamomile oil, a ylang-ylang oil, a basil oil, a turmeric oil, a ginger oil, an evening primrose oil, a tea tree oil, a jasmine oil, a rosemary oil, an eucalyptus oil, a myrrh oil, an orange oil, a clary sage oil, a helichrysum oil, a black pepper oil, a rose oil, a frankincense oil, a hemp oil, a borage oil or any combination thereof. In some cases, an oil can comprise, a fish oil, a turtle oil, a mink oil, a medium-chain triglyceride (MCT) oil, an olive oil, a vegetable oil, a coconut oil, a pumpkin seed oil, a walnut oil, a grapeseed oil, a peanut oil, a ghee oil, a sesame oil, a flaxseed oil, a sunflower seed oil, a canola oil, a poppy seed oil, analmond oil, an apricot kernel oil, a jojoba oil, a wheat germ oil, a safflower oil or any combination thereof.

[0054] In some embodiments, a composition described herein can comprise a sugar, a sweetening agent or any combination thereof. In some cases, a sugar can comprise granulated sugar, brown sugar, confectioners’ sugar, fruit sugar, baker’s special sugar, a sugar cube, cane sugar, pearl sugar, or any form of sugar. In some cases, a sugar can comprise a liquid sugar. A liquid sugar can comprise honey, a syrup, a corn syrup (e.g. high fructose com syrup), glucose syrup, maple syrup, molasses, a nectar (e.g. agave nectar) or any combination thereof. In some cases, sweetening agent can comprise a sugar alcohol (e.g. sorbitol, xylitol, mannitol), aspartame, saccharin, aspartame, acesulfame potassium, sucralose, advantame, neotame, stevia, isomalt maltodextrin or any combination thereof.

[0055] In some embodiments, a composition can comprise an inactive ingredient. In some cases an inactive ingredient can comprise beta-caryophyllene, beta-ocimene, caryophyllene oxide, caryophyllene, a terpinolene tincture, terpene oil, humulene, a cannabis plant wax, a nitrogenous compound, an amino acid or salt thereof, an aldehyde, lecithin, flour, chromium picolinate, an herb, a ketone, chocolate, pectin, citric acid, a glycoside, shortening, coffee, coffee beans, a spice, calcium ascorbate, vanilla, manganese proteinate, potassium bicarbonate, egg, carprofen, a pigment, milk, cranberry, a fruit, a berry, a vegetable, a pepper, ethanol, trisodium citrate, a peppercorn, a habanero, a jalapeno, chocolate liquor, cream, glucose sugar syrup, vanilla extract, sea salt, vanilla bean powder, sodium bicarbonate, sorbitol powder, salt, smoked salt, milk fat, milk cream powder, dried skim milk, sunflower lecithin, blueberries, white chocolate, FD& C dye and lake colors, blue 1, blue 2, red 40, yellow 5, yellow 6, green 3, titanium dioxide, Arabic gum, unsweeted chocolate, soy lecithin, butter, water, or any combination thereof. In some embodiments, a composition such as a balm or a lotion can comprise shea butter, cocoa butter, bees wax, mango butter, kokum butter, red cocoa butter, or any combination thereof. In some cases, a composition such as a cream can comprise hemp cream.

[0056] In some embodiments, a composition described herein can comprise a flavor. In some cases, a flavor can be a natural flavor, a flavor can be an artificial flavor, or a combination thereof. In some instances, a flavor can comprise acai berry, almond, amaretto, anise, apple, apricot, banana, bacon, bavarian cream, berry cola, birch beer, black licorice, black cherry, black currant, black walnut, blackberry, blue raspberry, blueberry, bourbon, bubble gum, butter, butter almond, butter milk, butter pecan, butter rum, butter toffee, butterscotch, cake batter, candy corn, caramel, caramel apple, caramel cream, carrot cake, champagne, cheesecake, cherry, cherry blossom, cherry cola, cherry cream spice, chocolate, chocolate cake, chocolate mint, cinnamon, cinnamon roll,coconut, coffee, cola, cookie dough, cotton candy, cranberry, cream soda, creme de menthe, cucumber, dill pickle, doughnut, elderberry, egg nog, eucalyptus, flan, fenugreek, fruity cereal, fruit punch, fuzzy navel, ginger ale, ginger beer, ginger lime, gingerbread, gingersnap, grand mariner, graham cracker, grape, grapefruit, green onion, hazelnut, honey, horchata, huckleberry, irish cream, irish whiskey, kettle corn, key lime, kiwi, lemon, lemon bar, lemon custard, lemon lime, lemon meringue pie, lemonade, lime, long island tea, macadamia nut, malted milk, mango, mango orange pineapple, maple, margarita, marshmallow, melon, melon kiwi, mint, mixed berry, mocha, mocha irish cream, mojito, moscow mule, nutmeg, orange, orange brandy, orange cream, orange mandarin, orange mango, orange pineapple, papaya, passion fruit, peach, peanut, pear, pecan, pecan roll, peppermint, pina colada, pineapple, pink lemonade, pistachio, plantation punch, plum, pomegranate, prickly pear, pumpkin, pumpkin pie, punch, quinine, raspberry, raspberry ginger ale, rock and rye, root beer, rum, sarsaparilla, sassafras, smoke, sour, strawberry, strawberry kiwi, spice, spearmint, tangerine, tart lemon, tequila, toasted coconut, toffee, tonic, tropical punch, tutti firutti, vanilla, vanilla cream, watermelon, white chocolate, whipped cream, wild cherry cream, wintergreen, or any combination thereof.

[0057] In some embodiments, a composition described herein can comprise a fragrance. In some cases, a fragrance can be a natural fragrance, an artificial fragrance or a combination thereof. In some cases, a fragrance can come from an essential oil or from a plant extract. In some cases, a fragrance can be a spice such as nutmag, can comprise a flavor or both. In some instances, the composition can comprise a fragrance, a paraben, a phthalate, an alcohol, or any combination thereof, for example less than about: 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% with respect to a total weight or a total volume of a composition. In some instances, the fragrance can be a perfume, cologne, an aftershave, or any combination thereof. In some instances, the composition can be free from a fragrance, a paraben, a phthalate, an alcohol, or any combination thereof.

[0058] In some cases, a composition herein does not comprise a color additive. In some cases, the composition can comprise a color additive. In some cases, the composition may contain an incidental ingredient such as a color additive in an insignificant level in the composition, for example less than about: 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% with respect to a total weight or a total volume of a composition. In some cases, the incidental ingredient may have no technical / structural, functional or any combination thereof effect in the composition, e.g., no an active ingredient.

[0059] In some cases, a composition provided herein can comprise a preservative. In some instances, the preservative can be an organic / natural compound, a synthetic compound or any combination thereof. In some instances, the preservative can be an antimicrobial, an antibacterial,an antifungal, an antiviral, an antiseptic, a detergent, or any combination thereof. In some cases, a cosmetic preservative can be a paraben, a formaldehyde releaser, an isothiazolinone, a phenoxyethanol, an organic acid, a quaternary ammonium compound, or any combination thereof. In some cases, a food preservative can comprise benzoates, nitrites, sulphites, sorbates or any combination thereof.

[0060] The composition described herein can be comprised in the form of a capsule, a tablet, a gummy, a liquid formulation, a suspension, a food, a drink, an oil, a tincture, a lotion, a cream, a balm, a solid, a gel, or any combination thereof. In some instances, the composition described herein can be in the form of a capsule, a tablet, a gummy, a candy, a chocolate, a beverage, or any combination thereof. In some instances, the composition described herein can be pharmaceutical formulation.Salts

[0061] Reference to a therapy, a compound, or a composition, includes reference to any salt, solvate, ester, or polymorph of the therapy, the compound, or the composition. A “salt” can include a pharmaceutically acceptable salt.

[0062] In some embodiments, the pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as tri ethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p- toluenesulfonate and the like; and amino acid salts such as arginate, asparginate, glutamate and the like. In some instances, a salt of a polypeptide or derivative thereof or a compound can be a Zwitterionic salt.

[0063] In some embodiments, a pharmaceutical composition comprising the salt of the pharmaceutically active ingredient can comprise an organic salt or an inorganic salt. In some cases, an organic salt may comprise a phosphinate (e.g., sodium hypophosphite), a hydrazinium salt, a urate, a diazonium salt, an oxalate salt, a tartrate, a choline chloride. An example of an inorganic salt may be sodium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, potassium chloride, sodium sulfate, calcium carbonate, calcium phosphate, or any combination thereof. In some cases, a salt comprises an HC1 salt, an ascorbic acid salt, a mandelic acid salt, an aspartic acid salt, a carbonic acid salt, a citric acid salt, a formic acid salt, a glutamic acid salt, alactic acid salt, a lauric acid salt, a maleic acid salt, a borate salt, a bitartrate salt, a palmitic acid salt, a phosphoric acid salt, or any combination thereof.Excipients, carriers, and diluents

[0064] In some embodiments, a composition can comprise an excipient, a carrier, and / or a diluent. In some embodiments, an excipient, a carrier, and / or a diluent can be a pharmaceutically acceptable excipient, carrier, and / or diluent. In some embodiments, a composition herein can comprise one or more of the following excipients: acacia, acesulfame potassium, acetic acid-glacial, acetone, acetyltributyl citrate, acetyltri ethyl citrate, adipic acid, agar, albumin, alcohol, alginic acid, aliphatic polyesters, alitame, almond oil, alpha tocopherol, aluminum hydroxide adjuvant, aluminum monostearate, aluminum oxide, aluminum phosphate adjuvant, ammonia solution, ammonium alginate, ammonium chloride, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butylene glycol, butylparaben, calcium acetate, calcium alginate, calcium carbonate, calcium chloride, calcium hydroxide, calcium lactate, calcium phosphate-dibasic anhydrous, calcium phosphate-dibasic dihydrate, calcium phosphate-tribasic, calcium silicate, calcium stearate, calcium sulfate, canola oil, carbomer, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, castor oil, castor oil-hydrogenated, cellulose-microcrystalline, cellulose-microcrystalline and carboxymethylcellulose sodium, cellulose-powdered, cellulose-silicified microcrystalline, cellulose acetate, cellulose acetate phthalate, ceratonia, ceresin, cetostearyl alcohol, cetrimide, cetyl alcohol, cetylpyridinium chloride, chitosan, chlorhexidine, chlorobutanol, chlorocresol, chlorodifluoroethane (hcfc), chlorofluorocarbons (cfc), chloroxylenol, cholesterol, citric acid monohydrate, coconut oil, colloidal silicon dioxide, coloring agents, copovidone, corn oil, corn starch and pregelatinized starch, cottonseed oil, cresol, croscarmellose sodium, crospovidone, cyclodextrins, cyclomethicone, denatonium benzoate, dextrates, dextrin, dextrose, dibutyl phthalate, dibutyl sebacate, diethanolamine, diethyl phthalate, difluoroethane (hfc), dimethicone, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, disodium edetate, docusate sodium, edetic acid, erythorbic acid, erythritol, ethyl acetate, ethyl lactate, ethyl maltol, ethyl oleate, ethyl vanillin, ethylcellulose, ethylene glycol stearates, ethylene vinyl acetate, ethylparaben, fructose, fumaric acid, gelatin, glucose — liquid, glycerin, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, glycine, glycofurol, guar gum, hectorite, heptafluoropropane (hfc), hexetidine, hydrocarbons (he), hydrochloric acid, hydrophobic colloidalsilica, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl betadex, hydroxypropyl cellulose, hydroxypropyl cellulose-low-substituted, hydroxypropyl starch, hypromellose, hypromellose acetate succinate, hypromellose phthalate, imidurea, inulin, iron oxides, isomalt, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, kaolin, lactic acid, lactitol, lactose-anhydrous, lactose-inhalation, lactose-monohydrate, lactose-monohydrate and corn starch, lactose-monohydrate and microcrystalline cellulose, lactose-monohydrate and povidone, lactose-monohydrate and powdered cellulose, lactose-spray-dried, lanolin, lanolin-hydrous, lanolin alcohols, lauric acid, lecithin, leucine, linoleic acid, macrogol 15 hydroxystearate, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate, maleic acid, malic acid, maltitol, maltitol solution, maltodextrin, maltol, maltose, mannitol, medium-chain triglycerides, meglumine, menthol, methionine, methylcellulose, methylparaben, mineral oil, mineral oil-light, mineral oil and lanolin alcohols, monoethanolamine, monosodium glutamate, monothioglycerol, myristic acid, myristyl alcohol, neohesperidin dihydrochalcone, neotame, nitrogen, nitrous oxide, octyldodecanol, oleic acid, oleyl alcohol, olive oil, palmitic acid, paraffin, peanut oil, pectin, pentetic acid, petrolatum, petrolatum and lanolin alcohols, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, phospholipids, phosphoric acid, polacrilin potassium, poloxamer, polycarbophil, polydextrose, poly (dl-lactic acid), polyethylene glycol, polyethylene oxide, polymethacrylates, poly(methyl vinylether / maleic anhydride), polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, polyvinyl acetate phthalate, polyvinyl alcohol, potassium alginate, potassium alum, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabisulfite, potassium sorbate, povidone, propionic acid, propyl gallate, propylene carbonate, propylene glycol, propylene glycol alginate, propylparaben, propylparaben sodium, pyrrolidone, raffinose, saccharin, saccharin sodium, safflower oil, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium alginate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium carbonate, sodium chloride, sodium citrate dihydrate, sodium cyclamate, sodium formaldehyde sulfoxylate, sodium hyaluronate, sodium hydroxide, sodium lactate, sodium lauryl sulfate, sodium metabisulfite, sodium phosphate — dibasic, sodium phosphate — monobasic, sodium propionate, sodium starch glycolate, sodium stearyl fumarate, sodium sulfite, sodium thiosulfate, sorbic acid, sorbitan esters (sorbitan fatty acid esters), sorbitol, soybean oil, starch, starch-pregelatinized, starch — sterilizable maize, stearic acid, stearyl alcohol, sucralose, sucrose, sucrose octaacetate, sugar-compressible, sugar-confectioner's, sugar spheres, sulfobutylether b-cyclodextrin, sulfur dioxide, sulfuric acid, sunflower oil, suppository bases — hard fat, tagatose, talc, tartaric acid, tetrafluoroethane (hfc), thaumatin, thimerosal, thymol, titanium dioxide, tragacanth, trehalose, triacetin, tributyl citrate, tricaprylin, triethanolamine, triethyl citrate, triolein, vanillin, vegetable oil-hydrogenated, vitamin e polyethylene glycol succinate, water, wax-anionic emulsifying, wax-carnauba, wax-cetyl esters, wax-microcrystalline, wax-nonionic emulsifying, wax-white, wax-yellow, xanthan gum, xylitol, zein, zinc acetate, or zinc stearate.

[0065] In some cases, a composition herein can comprise a carrier and / or a diluent. In some cases, a carrier or a diluent can be a pharmaceutically acceptable carrier and / or diluent. In some instances, a carrier or diluent can comprise a water, an alcohol, a salt solution (e.g., saline), or a mixture thereof. In some instances, a carrier can comprise a carbohydrate (e.g., a sugar), a buffer, a salt, a pH adjuster, or any combination thereof. In some cases, sodium phosphate, citric acid, acetic acid, tromethamine, histidine, gluconic, lactic acid, tartaric acid, aspartic acid, glutamic acid, a citric acid cycle intermediate, or any combination thereof can be a buffer. In some cases, citrate can be used as a buffer. In some cases, a carrier can be a substrate used in the process of drug delivery. In some cases, a carrier can contribute a product’s attributes such as stability, biopharmaceutical profile, and / or appearance. In some cases, a carrier can be an organic excipient.

[0066] Also described herein are methods of making the compositions described herein such as pharmaceutical compositions. In some cases, a method of making can comprise contacting an ingredient with another ingredient, or a plurality of ingredients and mixing to a homogenous or substantially homogenous composition. In some cases, the composition can be a heterogeneous or substantially heterogeneous mixed composition. In some cases, a method of making can comprise contacting an ingredient with another ingredient, or a plurality of ingredients and mixing to a substantially heterogeneous composition.Treatment of Diseases

[0067] Provided herein are compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids of for the treatment of reproductive cancers. In some embodiments, reproductive cancer is endometrial cancer, uterine cancer, an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof. In some embodiments the reproductive cancer spreads through lymphatic pathways. In some embodiments the lymphatic pathways comprise lymph nodes. In some embodiments, the compositions, methods, and systems provided herein are administered via nonparenteral or parenteral administration, reaching the reproductive organs and / or lymph nodes.In some embodiments the compositions, methods, and systems provided herein synergize with standard of care cancer treatments.

[0068] In some embodiments, a composition and / or therapy herein can be used to treat a cancer. In some cases, a cancer can comprise an endometrial cancer. In some cases, a cancer can comprise an endometrial adenocarcinoma. In some cases, a cancer can comprise a clear cell carcinoma. In some cases, a cancer can comprise an adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, or any combination thereof. In some cases, a cancer can comprise a uterine cancer. In some cases, a cancer can comprise a uterine sarcoma. In some cases, a cancer can comprise a carcinoma, a sarcoma, a leukemia, a lymphoma, a myeloma, a brain cancer, a spina cord cancer, or any combination thereof. In some cases, a cancer can comprise a squamous cell carcinoma, an adenocarcinoma, a transitional cell carcinoma, a basal cell carcinoma, or any combination thereof. In some cases, a sarcoma can comprise a bone sarcoma, a soft tissue sarcoma, or any combination thereof. In some cases, the cancer can comprise a primary, a metastatic, or a recurrent cancer. In some cases, the adenocarcinoma can comprise a primary adenocarcinoma, a metastatic adenocarcinoma, or a recurrent adenocarcinoma.

[0069] In some cases, a cancer can be a low grade, a moderate grade, or a high grade. In some cases, an endometrial cancer can be a low grade, a moderate grade, or a high grade. In some cases, a cancer can be a grade 1 tumor, a grade 2 tumor, or a grade 3 tumor. In some cases, an endometrial cancer can be a grade 1 tumor, a grade 2 tumor, or a grade 3 tumor.

[0070] In some embodiments, a composition and / or therapy herein can be used to treat an Acute Lymphoblastic Leukemia (ALL), an acute Myeloid Leukemia (AML), an adolescent cancer, an adrenocortical carcinoma, AIDS-Related cancers, a Kaposi Sarcoma, a AIDS-Related Lymphoma, a primary CNS lymphoma, an anal cancer, an appendix cancer, an astrocytomas, an atypical teratoid / rhabdoid tumor, a basal cell carcinoma of the skin, a bile duct cancer, a bladder cancer, a bone cancer, brain tumors, a breast cancer, bronchial tumors, a Burkitt lymphoma, a carcinoma of unknown primary, a central nervous system, an atypical teratoid / rhabdoid tumor, medulloblastoma and other CNS embryonal tumors, a germ cell tumor, a primary CNS lymphoma, a cervical cancer, a childhood cancer, a cholangiocarcinoma, a chordoma, a chronic lymphocytic leukemia (CLL), a chronic myelogenous leukemia (CML), a chronic myeloproliferative neoplasms, a colorectal cancer, a craniopharyngioma, a cutaneous t-cell lymphoma, embryonal tumors, medulloblastoma and other central nervous system, an endometrial cancer, an ependymoma, an esophageal cancer, an esthesioneuroblastoma, an Ewing sarcoma, an extracranial germ cell tumor, an extragonadal germ cell tumor, an eye cancer, an intraocular melanoma, a retinoblastoma, a fallopian tube cancer,a gallbladder cancer, a gastric (stomach) cancer, a gastrointestinal neuroendocrine tumors, gastrointestinal stromal tumors (gist), germ cell tumors, a gestational trophoblastic disease, a hairy cell leukemia, head and neck cancer, heart tumors, a hepatocellular (liver) cancer, a histiocytosis, Langerhans cell, a Hodgkin lymphoma, a hypopharyngeal cancer, an intraocular melanoma, islet cell tumors, pancreatic neuroendocrine tumors, a kidney (renal cell) cancer, a Langerhans cell histiocytosis, an laryngeal cancer, leukemia, a lip and oral cavity cancer, a liver cancer, a lung cancer (non-small cell, small cell, pleuropulmonary blastoma, pulmonary inflammatory myofibroblastic tumor, and tracheobronchial tumor), a lymphoma, a male breast cancer, a melanoma, a melanoma, intraocular, a Merkel cell carcinoma, a mesothelioma, malignant, a metastatic cancer, a metastatic squamous neck cancer with occult primary, a midline tract carcinoma with nut gene changes, a mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndromes, myelodysplastic / myeloproliferative neoplasms, a myelogenous leukemia, chronic (cml), a myeloid leukemia, acute (AML), myeloproliferative neoplasms, chronic, a nasal cavity and paranasal sinus cancer, a nasopharyngeal cancer, a neuroblastoma, neuroendocrine tumors, a non-Hodgkin lymphoma, a non-small cell lung cancer, an oral cancer, lip and oral cavity cancer and oropharyngeal cancer, an osteosarcoma and undifferentiated pleomorphic sarcoma of bone treatment, an ovarian cancer, a pancreatic cancer, pancreatic neuroendocrine tumors, papillomatosis, a paraganglioma, a paranasal sinus and nasal cavity cancer, a parathyroid cancer, a penile cancer, a pharyngeal cancer, a pheochromocytoma, a pituitary tumor, a plasma cell neoplasm / multiple myeloma, a pleuropulmonary blastoma, a pregnancy and breast cancer, a primary central nervous system (CNS) lymphoma, a primary peritoneal cancer, a prostate cancer, a pulmonary inflammatory myofibroblastic tumor, a rectal cancer, a recurrent cancer, a renal cell (kidney) cancer, a retinoblastoma, a rhabdomyosarcoma, a salivary gland cancer, a sarcoma, a rhabdomyosarcoma, a vascular tumor, an Ewing sarcoma, a osteosarcoma, a soft tissue sarcoma, a uterine sarcoma, Sezary syndrome, a skin cancer, a small cell lung cancer, a small intestine cancer, a soft tissue sarcoma, a squamous cell carcinoma of the skin, squamous neck cancer with occult primary, metastatic, a stomach (gastric) cancer, a T-cell lymphoma, cutaneous, a testicular cancer, a throat cancer, an nasopharyngeal cancer, an oropharyngeal cancer, a hypopharyngeal cancer, a thymoma and thymic carcinoma, a thyroid cancer, a tracheobronchial tumors, an transitional cell cancer of the renal pelvis and ureter, a ureter and renal pelvis, a transitional cell cancer (kidney (renal cell) cancer), a urethral cancer, a uterine cancer, endometrial, a uterine sarcoma, a vaginal cancer, a vascular tumors (soft tissue sarcoma), an vulvar cancer, a Wilms tumor, or any combination thereof.

[0071] In some embodiments the compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids of for the treatment of reproductive cancers provided herein synergize with standard of care cancer treatments. In some embodiments the compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids of for the treatment of reproductive cancers provided herein synergize with an additional therapy. In some embodiments the compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids provided herein are administered in combination with standard of care cancer treatments (co-therapy).

[0072] In some embodiments, an additional therapy (e.g., a second therapy) can be administered to a subject in a unit dose. In some cases, 1, 2, 3, 4, 5 or more therapies can be administered to a subject in need thereof. In some cases, an additional therapy can be comprised in a composition with a cannabinoid (e.g., CBD). In some cases, an additional therapy can be in a different composition, which does not include the cannabinoid. In some cases, the additional therapy can be administered consecutively or concurrently to a first therapy, which can be a cannabinoid such as CBD.

[0073] In some cases, an additional therapy can be a cancer therapy and a cancer therapy can comprise a non-steroidal anti-inflammatory (NSAID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and / or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, or any combination thereof.

[0074] In some cases, a NSAID can comprise an ibuprofen, a naproxen, a diclofenac, a celecoxib, a mefenamic acid, an etoricoxib, an indomethacin, an aspirin, a ketorolac, a diclofenac, a meloxicam, a ketorolac, an esomeprazole, a nabumetone, a indomethacin, a mefenamic acid, a piroxicam, a diclofenac, a diflunisal, a sulindac, a ketoprofen, a tolmetin, a fenoprofen, a salt of any of these, or any combination thereof. In some cases, a platinum analogue can comprise an eloxatin, a cisplatin, a carboplatin, an oxaliplatin, a nedaplatin, a lobaplatin, a heptaplatin, a triplatin tetranitrate, a phenathriplatin, a picoplatin, a satraplatin, a salt of any of these, or any combination thereof. In some cases, a tyrosine kinase inhibitor can comprise a dasatinib, an imatinib, a gefitinib, an erlotinib, a vemurafenib, a sorafenib, a ponatinib, a nilotinib, a masitinib, an axitinib, a pazopanib, a sunitinib, a salt of any of these, or any combination thereof. In some cases, an anthracycline can comprise an adriamycin, a caelyx, a cerubidine, a cytarabine, a daunorubicin, a doxorubicin, a epirubicin, a idarubicin, a mitoxantrone, a pharmorubicin, a valrubicin, a daunorubicin, a cytarabine, a salt of any of these, or any combination thereof. In somecases, a taxane can comprise a paclitaxel, a docetaxel, a cabazitaxel, a salt of any of these, or any combination thereof. In some cases, an mTOR and / or AKT targeting therapy can comprise a rapamycin, AZD 8055, a sirolimus, a temsirolimus, an everolimus, a ridaforolimus, a deforolimus, an apitolisib, MK-2206, a afuresertib, a KRX-0401, a Honokiol, a Torinl, a PP242, a PP30, a Ku-0063794, a WAY-600, a WYE-687, a WYE-354, an INK128, an AZD8055, an OSI-02, a salt of any of these, or any combination thereof. In some cases, a sphingolipid metabolism targeting therapy can comprise a cytotoxic retinoid, a fenretinide(4-HPR), a sphingosine kinase inhibitor, a fenretinide, a a-galactosylceramide, a ABC294640, a SKI-II, a sonepcizumab, a FTY720, a tamoxifen, a synthetic ceramide, a salt of any of these, or any combination thereof. In some cases, a p53 targeting therapy can comprise a RG7112, an idasanutlin, a SAR405838, an alrizomadlin, a MK-8242, a TAS-102, a talazoparib, a APR-246, a ALT-801, a salt of any of these, or any combination thereof. In some cases, a PARP inhibitor can comprise an olaparib, a niraparib, a rucaparib, a talazoparib, a salt of any of these, or any combination thereof.

[0075] In some cases, an additional therapy can be a cancer therapy. In some cases, a cancer therapy can comprise a chemotherapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, an immune therapy, or any combination thereof.

[0076] In some cases, a hyperthermia therapy can comprise a local hyperthermia therapy, a regional hyperthermia therapy, or a whole-body hyperthermia therapy. In some cases, a photodynamic therapy can comprise a lamp or laser photodynamic therapy, a natural day light photodynamic therapy, or any combination thereof. In some cases, a radiation therapy can comprise a 3D conformal radiation therapy (3DCRT), an image guided radiation therapy (IGRT), a Intensity modulated radiation therapy (IMRT), a volumetric modulated arc therapy (VMAT), a brachytherapy, an intraoperative radiation therapy (IORT), a stereotactic radiosurgery (SRS), a proton therapy, a Stereotactic body radiation therapy (SBRT), an external beam radiation therapy, an internal radiation therapy, a brachytherapy, a total body irradiation therapy, or any combination thereof. In some cases, a radiation therapy can comprise a vaginal brachytherapy, a pelvic radiation therapy, or both. In some cases, a surgery can comprise a cryosurgery, a laser surgery, an electrosurgery, a microscopically controlled surgery, a curative surgery, a preventive surgery, a diagnostic surgery, a staging surgery, a debulking surgery, a palliative surgery, a restorative surgery, or any combination thereof. In some cases, a surgery can comprise a radical hysterectomy, a bilateral salpingo-oophorectomy, a lymph node surgery, a omentectomy, a tumor debulking, or any combination thereof.

[0077] In some cases, a hormone therapy can comprise an anastrozole, an elacestrant, an exemestane, a fulvestrant, a goserelin, a letrozole, a leuprolide, a leuprolide acetate, a megestrol, a tamoxifen, a toremifene, a salt of any of these, or any combination thereof. In some cases, a hormone therapy can comprise an euprolide, a goserelin, a triptorelin, a degarelix, a histrelin, a bicalutamide, a flutamide, a nilutamide, salt of any of these, or any combination thereof. In some cases, a hormone therapy can comprise a progestin, such as a medroxyprogesterone, a medroxyprogesterone acetate, a megestrol acetate, a megestrol, a progesterone, a salt of any of these, or any combination thereof. In some cases, a hormone therapy can comprise a letrozole, an anastrozole, an exemestane, a salt of any of these, or any combination thereof.

[0078] In some cases, a chemotherapy can comprise an alkylating agent. In some cases, an alkylating agent can comprise an altretamine, a bendamustine, a busulfan, a carboplatin, a chlorambucil, a cisplatin, a cyclophosphamide, a dacarbazine, a ifosfamide, a mechlorethamine, a melphalan, an oxaliplatin, a procarbazine, a temozolomide, a thiotepa, a trabectedin, a carmustine, a lomustine, a streptozocin, a temozolamide, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise an antimetabolite. In some cases, an antimetabolite can comprise a 5-fluorouracil, a 6-mercaptopurine, an azacitidine, a capecitabine, a cladribine, a clofarabine, a cytarabine, a decitabine, a floxuridine, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nelarabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine / tipiracil, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise a topoisomerase inhibitor. In some cases, a topoisomerase inhibitor can comprise an etoposide, an irinotecan, an irinotecan liposomal, a mitoxantrone, a teniposide, a topotecan, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise a mitotic inhibitor. In some cases, a mitotic inhibitor can comprise a cabazitaxel, a docetaxel, a nab-paclitaxel, a paclitaxel, a vinblastine, a vincristine, a vincristine liposomal, a vinorelbine, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise an antitumor antibiotic. In some cases, an antitumor antibiotic can comprise a daunorubicin, a doxorubicin, a doxorubicin liposomal, an epirubicin, an idarubicin, a mitoxantrone, a valrubicin, a bleomycin, a dactinomycin, a mitomycin-c, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise an all-trans-retinoic acid, an arsenic trioxide, an asparaginase, an eribulin, an ixabepilone, a mitotane, an omacetaxine, a pegaspargase, a procarbazine, a romidepsin, a vorinostat, a salt of any of these, or any combination thereof. In some cases, a chemotherapy can comprise a corticosteroid. In some cases, a corticosteroid can comprise a dexamethasone, a hydrocortisone, a methylprednisolone, a prednisolone, a prednisone, a salt of any of these, or any combination thereof. In some cases, achemotherapy can comprise a paclitaxel, a carboplatin, a doxorubicin, a liposomal doxorubicin, a cisplatin, a docetaxel, a salt of any of these, or any combination thereof.

[0079] In some cases, an immunotherapy can comprise a checkpoint inhibitor. In some cases, an immunotherapy can comprise a PD-1 inhibitor (e.g., pembrolizumab, nivolumab, cemiplimab, a salt of any of these, or a biosimilar of any of these), a PD-L1 inhibitor (e.g., atezolizumab, avelumab, durvalumab a salt of any of these, or a biosimilar of any of these), a CTLA-4 inhibitor (e.g., ipilimumab, a salt thereof, or a biosimilar of any of these), a TIGIT inhibitor, a Tissue factor (TF) inhibitor (e.g., tisotumab vedotin-tftv, a salt thereof, or a biosimilar of any of these), a TIGIT inhibitor, a ATAR inhibitor, a B7-H3 inhibitor, a B7-H4 inhibitor, a BTLA inhibitor, an IDO inhibitor, a KIR inhibitor, a LAG inhibitor, a N0X2 inhibitor, a SIGLEC7 inhibitor, a SIGLEC9 inhibitor, a TIM3 inhibitor, a VISTA inhibitor, or any combination thereof. In some cases, an immunotherapy can comprise a monoclonal antibody, a bispecific antibody, a conjugated antibody (e.g., an antibody drug conjugant), a oncolytic virus therapy (e.g., talimogene laherparepvec, a salt thereof, or a biosimilar of any of these), a cancer vaccine (e.g., cervarix, Gardasil, Gardasil-9, HEPLISAV-B, sipuleucel-T, Bacillus Calmette-Guerin (BCG)). In some cases, an immunotherapy can comprise an immune system modulator. In some cases, an immunotherapy can comprise a brentuximab vedotin, an Ado-trastuzumab emtansine, a biosimilar of any of these, a salt of any of these, or any combination thereof. In some cases, a immunotherapy can comprise a cytokine. In some cases, a cytokine can comprise an interferon, an interleukin 2, or any combination thereof. In some cases, an immune system modulator can comprise an interleukin (e.g., IL-2), an interleukin inhibitor (e.g., an IL-6 inhibitor), an antihistamine, an immunomodulator (e.g., imiquimod, lenalidomide, pomalidomide, thalidomide, a salt thereof, or a derivative thereof), or any combination thereof. In some cases, a stem cell therapy can comprise a hematopoietic stem cell therapy, a mesenchymal stem cell therapy, a neural stem cell therapy, an induced pluripotent stem cell therapy, an epithelial stem cell therapy, or any combination therapy. In some cases, a stem cell therapy can comprise a an autologous stem cell, an allogeneic stem cell therapy, or a syngeneic stem cell therapy. In some cases, an immunotherapy can comprise a lenvatinib, a bevacizumab, a biosimilar of any of these, a salt of any of these, or any combination thereof. In some cases, an cancer therapy can comprise an everolimus, a temsirolimus, a salt of any of these, or any combination thereof.

[0080] In some embodiments, a therapy herein (e.g., a primary therapy and / or an additional therapy) can be administered to a subject in a unit dose. A unit dose that is administered to a patient may comprise from about: 0.0001 g (gram) to about 500 g, 0.001 g to about 250 g, 0.01 g to about 100 g, 0.1 g to about 50 g, 10 g to about 25 g, 0.1 g to about 5 g, 0.1 g to about 1 g, or 1 g to about10 g of a pharmaceutical composition of the current disclosure. In some embodiments, a pharmaceutical composition comprises an amount of at least about, or equal to about: 0.0001 g, 0.001 g, 0.01 g, 0.1 g, 0.5 g, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g, 17 g, 18 g, 19 g, 20 g, 21 g, 22 g, 23 g, 24 g, 25 g, 26 g, 27 g, 28 g, 29 g, 30 g, 31 g, 32 g, 33 g, 34 g, 35 g, 36 g, 37 g, 38 g, 39 g, 40 g, 41 g, 42 g, 43 g, 44 g, 45 g, 46 g, 47 g, 48 g, 49 g, 50 g, 51 g, 52 g, 53 g, 54 g, 55 g, 56 g, 57 g, 58 g, 59 g, 60 g, 61 g, 62 g, 63 g, 64 g, 65 g, 66 g, 67 g, 68 g, 69 g, 70 g, 71 g, 72 g, 73 g, 74 g, 75 g, 76 g, 77 g, 78 g, 79 g, 80 g, 81 g, 82 g, 83 g, 84 g, 85 g, 86 g, 87 g, 88 g, 89 g, 90 g, 91 g, 92 g, 93 g, 94 g, 95 g, 96 g, 97 g, 98 g, 99 g, 100 g, 125 g, 150 g, 175 g, 200 g, 250 g, 300 g, 350 g, 400 g, 450 g, 500 g, or more of an active ingredient of the current disclosure. In some embodiments, a pharmaceutical composition comprises an amount of at least about, or equal to about: 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 750 mg, 1000 mg, 1500 mg, 2000 mg, 2500 mg, 3000 mg, 3500 mg, 4000 mg, 4500 mg, or 5000 mg or more of an active ingredient of the current disclosure. In some embodiments, a treatment herein can comprise from 0.001 g to about 2 g of an active ingredient of the current disclosure in a single dose. In some embodiments, a treatment herein can comprise from about: 1 mg to about 100 mg, 1 mg to about 25 mg, 5 mg to about 30 mg, 10 mg to about 50 mg, 25 mg to about 40 mg, 35 mg to about 60 mg, 45 mg to about 70 mg, 40 mg to 80 mg, 75 mg to about 150 mg, 15 mg to about 75 mg, 50 mg to about 100 mg, 75 mg to about 500 mg, 250 mg to about 1500 mg, 1000 mg to 3000 mg, or 1500 mg to about 5000 mg of an active ingredient of the current disclosure in a single dose.

[0081] In some cases, a subject can be diagnosed with a cancer, such as an endometrial cancer. In some cases, the diagnosis can occur before, during or after treatment. In some cases, the diagnosis can comprise a physical exam, a medial imagining exam, a biopsy, a blood test, or any standard diagnostic technique.Administration

[0082] Provided herein are compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids of for the treatment of reproductive cancers. In some embodiments, the compositions, methods, and systems provided herein are administered via nonparenteral administration or parenteral administration. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches the reproductive organs and / or lymph nodes after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches the cells comprising cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids reaches CBD receptors in the cells comprising cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids modulates cancer-associated cell signaling after administration as described herein. In some embodiments, the composition comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and / or flavonoids modulates immunoexpression after administration as described herein.

[0083] A therapy or a composition provided herein can be administered by any method. In some embodiments, a composition and / or an additional therapeutic can be administered orally, for example, in the form of a liquid, a tablet, a pill, or a capsule. In some cases, a composition and / or an additional therapy can be administered by intrauterine delivery or vaginal delivery. In some cases, a composition and / or an additional therapy can be delivered by parenchymal injection, intrathecal injection, intra-ventricular injection, intra-tumoral injection, intra-ci sternal injection, or any combination thereof. In some cases, a method of administration can be by inhalation, intraarterial injection, intracerebroventricular injection, intracisternal injection, intramuscular injection, intraorbital injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection, or any combination thereof. In some cases, delivery can comprise buccal administration, by infusion administration, nasal administration, otic administration, ophthalmic administration, sublingual administration, subdermal administration, or transdermal administration. Delivery can include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular or infusion), oral administration, nasal administration, inhalation administration, anal administration, intraduodenal administration, rectal administration. In some cases, delivery can include delivery of a compositionby a surgery, or by an injection. Delivery can include topical administration to an external surface of a surface, such as a skin. In some cases, a therapy provided herein can be administered consecutively or concurrently to an additional therapy.

[0084] In some instances, a composition or pharmaceutical composition may be in the form of a capsule, a pellet, a tablet, a gummy, an oil, a syrup, a liquid, a tincture, a lotion, a cream, a balm, a food, a beverage, an oil, a suppository, a liquid for injection (which can be, for example, an intra venous liquid, an intra muscular liquid, a subcutaneous liquid), or any combination thereof

[0085] In some embodiments, administering of a therapy and / or composition can be performed at least about: 1 time per day, 2 times per day, 3 times per day, 4 times per day, 5 times per day, 6 times per day, 7 times per day, or more than 7 times per day. In some cases, administering can be performed daily, weekly, monthly, or as needed. In some cases, administration can be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 times a week. In some cases, administration can be performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 times a month.

[0086] Administration of a composition or a therapy provided herein can be performed for a treatment duration of at least about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 days consecutive or nonconsecutive days. In some cases, a treatment duration can be from about: 1 to about 30 days, 1 to about 60 days, 1 to about 90 days, 30 days to about 90 days, 60 days to about 90 days, 30 days to about 180 days, from 90 days to about 180 days, or from 180 days to about 360 days.

[0087] In some aspects, the composition may be administered as needed. In some embodiments, administration of a composition or a therapy provided herein can be performed for a treatment duration of at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 6 years, at least about 7 years, at least about 8 years, at leastabout 9 years, at least about 10 years, at least about 15 years, at least about 20 years, or for life. In some cases, administration can be performed repeatedly over a lifetime of a subject, such as once a month, once a week, or once a year for the lifetime of a subject. Administration can be performed repeatedly over a substantial portion of a subject’s life, such as once a month, once a week, or once a year for at least about 1 year, 5 years, 10 years, 15 years, 20 years, 25 years, 30 years, or more.Kits

[0088] Kits and articles of manufacture are also described for use with the compositions described herein. In some cases, a kit can comprise a composition provided herein. In some cases, a kit can comprise a container. In some instances, a container can be a plastic container, a glass container, a metal container, any suitable material, or a mixture of materials. In some embodiments, a kit comprises a cannabinoid and / or an additional therapy provided herein, and instructions for use in administering the composition to a subject to treat a cancer. In some embodiments, such kits can include a carrier, a packaging, and / or container. In some embodiments, the container can comprise capsules, vials, or tubes. In some embodiments, the kit can be accompanied by instructions for administration. In some embodiments, a kit can be in a packaging.ExamplesExample 1: Immunohistochemistry of CBD receptors in cancer cells

[0089] To detect expression of cannabinoid receptors an immunohistochemistry analysis was performed on endometrial cancer cells. Sample images for the immunohistochemistry analysis and diagnosis information are shown in FIGS. 1-10. The immunohistochemistry cellular localization of the cannabidiol (CBD) receptor is shown in brown (colored throughout the cells) and expressed in medium / high levels in the cells. The CBD receptor can be found at least in the nucleus, and / or the cytoplasm. The figures show approximately 90% of endometrial cancer specimens have medium and / or high immunoexpression (nuclear and cytoplasmic) of cannabidiol receptors. In the one clear cell carcinoma specimen, which is shown in FIG. 1, there was not medium or high immunoexpression, nevertheless there was still immunoexpression present, thereby identifying the presence of CBD receptors even in this group of rare cancers of the endometrium. Details and pictorial support of 10 patient cancer samples are shown in FIGS. 1-10. Specimens from an additional 10 patients with metastatic disease were studied and similar results were obtained.

[0090] The immunohistochemistry lab report details for FIGS. 1-10 are found in Table 3 and Table 4Table 3: Antibodies for Immunohistochemistry (IHQ) TechniqueTable 4: Sample characteristics and origin data

[0091] The identification of this receptor in cancer cells shows CBD and other cannabinoids can be used as a therapy for cancer treatment in endometrial cancers. Similarly, the presence of CBD receptors on these cancers suggests the administration of a composition comprising CBD, terpenes, and / or flavonoids can produce improved cancer reduction compared to a standard of care treatment for reproductive cancer without administration of the composition. As such, CBD, terpenes, and / or flavonoids can be used with or without standard of care treatments for the treatment of endometrial cancers.Example 2: Immunohistochemistry of PPARa in endometrial cancer cells

[0092] An immunostaining assay was performed to identify different types of endometrial cancer and identify the disease severity for each sample as related to a FIGO grade, which is the Federation of Gynecology and Obstetric’s 3-tier system for grading tumors (Grade 1, 2, and 3) based on the amount of glandular versus solid growth present in the sample.

[0093] The immunostaining assay was designed to detect peroxisome proliferator-activated receptor alpha (PPARa), a nuclear receptor protein that is elevated in endometrial cancer.In brief, endometrial tissue biopsies from 20 patients were isolated, formalin fixed and paraffin embedded. 5 um biopsy sections were cut and immunostained according to the immunohistochemistry assay described in Vasconcellos et al, 2024. The 5 um biopsy sections were then dewaxed in xylene, rehydrated with a graded ethanol series 100, 95,70 and rinsed in distilled water. For antigen retrieval, the sections were immersed in sodium citrate 10 mmol / L, pH 6.0) and Tween solution for 3 minutes at high potency in the microwave. Then, the sections were treated with a 3% hydrogen peroxide solution for 25 min to block endogenous peroxidase activity. After the sections were blocked with 3% bovine serum albumin (BSA) for 30 min at room temperature, the sections were incubated on slides with anti-PPAR alpha antibody at 4 °C overnight. Phosphate-buffered saline (PBS) was administered to negative controls. After incubation, the sections were rinsed in PBS 3 times. The slides were then incubated with antirabbit antibody (abeam) for 30 min at room temperature. After being washed with PBS the slides were incubated with streptavidin peroxidase complex (abeam). The slides were then incubated with 3,3’-diaminobenzidine tetrahydrochloride dihydrate in peroxidase solution (DAB, Abeam) and counterstained with Harris Haematoxylin for 30 seconds. Finally, all slides were mounted on glass slides with rapid mounting medium for microscopy.Whole slide imaging was performed for all slides, and images were collected as captured by a digital slide scanner (e.g., Motic Easy One scanner and MOTIC assistant software). The immunohistochemical staining was assessed with Fiji-based image analysis (e.g., Just ImageJ). For the image analysis, 2 observers without access to patient information captured 20 images per patient sample. A series of 18-20 images of each section for each targeted PPARa protein were randomly extracted to obtain an average value for statistical comparison (macro). Brown color area and high intensity were selected to define the PPARa immunostaining area and intensity (InDen). A macro was generated and equally applied to all images (Batch macro process).Measurements of immunostaining area and intensity were determined. The InDen was defined as the integrated density. The pixels intensity in the brown color area detailed areas with high PPARa immunoexpression in the endometrium.

[0094] The assay results are detailed in Table 5 below.Table 5: Immunohistochemistry of PPARa receptors in cancer cellsExample 3: Immunostaining PPARa receptors in uterine cancer tissue

[0095] An immunostaining assay was performed to identify the association between percent immunostaining area intensity and FIGO grade, which is the Federation of Gynecology and Obstetric’s 3-tier system for grading tumors (Grade 1, 2, and 3) based on the amount of glandular versus solid growth present in the sample.

[0096] The immunostaining assay was designed to detect peroxisome proliferator-activated receptor alpha (PPARa), a nuclear receptor protein that is elevated in uterine cancer. The immunostaining assay was performed as described in Example 2 adjusted to cover n=21.

[0097] Several staining measurements performed on 21 tissue specimens resulted in the percent stain area data detailed in Table 6. The number of valid staining measurements performed on each specimen ranged from 6 to 20. Some records recorded percentages greater than 100%.These values were considered missing for this analysis. There were 34 records with missing staining values (see Table 6: N Valid and N Missing). Table 6 summarizes the median level of percent area immunostain positive measured and the interquartile range (IQR) for each specimen. The specimens' median percent area stain levels ranged from 0.15% to 28.4%. The lowest reported value overall observations was 1.03%, and the highest value was 100%.Table 6: Percent Area Intensity per SamplePercent Area intensitySpecimen ID batch FIGO Grade Median IQR Min Max IM Valid N Missing1 2 3 11.120 10.427 1.67 30.650 14 0 2 2 1 27.130 10.150 10.24 36.360 20 0 3 2 1 0.215 0.667 0.01 1.030 20 0 4 2 1 5.275 7.450 0.15 19.350 20 0 5 2 3 3.085 6.100 0.17 16.170 20 0 6 2 3 28.420 6.565 12.63 38.470 20 0 7 2 3 9.930 5.342 2.62 16.380 20 0 8 2 1 1.100 1.445 0.02 13.920 19 1 9 2 3 10.455 7.382 0.07 36.400 6 1 10 2 1 0.160 1.180 0.02 13.910 13 8 11 2 1 0.600 2.010 0.02 3.310 17 2 12 1 1 1.805 4.488 0.15 19.580 20 0 13 1 1 1.950 2.713 0.14 9.820 18 2 14 1 1 3.229 7.755 0.04 13.430 19 1 15 1 3 0.881 2.781 0.01 99,990 10 9 16 1 3 1.500 3.835 0.26 5.780 19 1 17 1 1 3.155 4.575 0.04 9.850 16 4 18 1 1 0.325 1.545 0.02 6.752 16 5 19 1 1 0.360 0.795 0.01 4.780 14 3 20 1 4 0.145 0.555 0.01 21.880 20 6 21 1 3 1.300 1.945 0.06 16.560 20 0

[0098] The laboratory measurements were performed in two batches. FIG. 11 summarizes the unadjusted percent area stain reported for each specimen by batch. The horizontal line inside each box indicates the median percent area stain for the specimen and the ends of the boxes mark the 25th and 75th percentiles. Each specimen was graded according to the FIGO Grading System. The FIGO grade of each specimen is detailed in FIG. 11. There were 12 grade 1 specimens and 8 grade 3. One specimen (ID=20) had no grade assigned. Also, one specimen (ID=15) had one measured percent area stain of 100%, but this value does not appear in this figure due to scaling. However, this measurement is included in the regression analysis.

[0099] The overall median percent area stain for batch 1 is 1.4% and 5.3% for batch 2. These are designated with a thick dashed line in FIG. 11. Parenthetically, 6 of 12 (50%) of grade 1 and 5 of 8 (62.5%) of grade 3 had specimen-median percent area stains greater than their respective batch medians.

[0100] Percent area stain was analyzed using a Bayesian mixed model constructed using the R (version: 4.2.1, R Core Team (2022)) package brms (version: 2.20.4, Bürkner (2017)). Percent area stain was the dependent variable and its values were modeled as a beta distribution using a logit link function. The specimen’s FIGO grade and its assigned batch were incorporated into the model as fixed-effect factors. The prior distribution of the intercept, as well as the FIGO grade 3 and batch coefficients were student t (3, 0, 2.5). Specimen ID was included as a random effect. Homogeneity of the variance (dispersion) was investigated as a function of either batch or specimen ID. The R package bayestestR (version: 0.15.2, Makowski, Ben-Shachar, and Lüdecke (2019)) was used to calculate bayesian p-values. The marginaleffects package was used to estimate and compare posterior predicted values. The final model included FIGO grade and batch as fixed effects without an interaction term and accounted for over-dispersion among specimens. The Bayesian mixed model results show the posterior predicted mean percentage of area stain by FIGO grade for each batch as detailed in Table 7 and FIG. 12. The difference in percent area stain between the grade 3 and grade 1 averaged over both batches is 7.1% (95% CI: 0.4%-15.9%). The probability that percent area stain in grade 3 specimens exceeds grade 1 (Bayesian probability of direction) is 0.98. Using a Region of Practical Equivalence (ROPE) of (log scale: -0.18, 0.18), the percentage of the full posterior distribution for the FIGO grade 3 coefficient being within the ROPE is 0.018% (Bayesian p-value=0.018). Overall, the results show FIGO grade 3 uterine cancers are associated with a higher percent area stain than FIGO grade 1 uterine cancers.Table 7: Predicted Mean Percent Area Stain FIGO grade

[0101] Table 8 summarizes the qualitative immunostaining in the epithelial lining, connective tissue, and myometrium of 12 distinct uterine cancer specimens. The qualitative immunostaining was classified as (0=none?), 1=low, 2=medium, and 3=high.Table 8: Qualitative Staining Intensity and FIGO gradeQualitative Staining IntensitySpecimen ID FIGO Grade Eplth. lin. Conn. Tiss. Myomet1 3 2 08 1 3 1 0 13 1 2 2 15 3 1 1 16 3 2 3 2 18 1 2 0 0 21 3 2 0 2Table 9: Qualitative Staining Intensity and FIGO grade

[0102] A Wilcoxon rank sum test was used to assess the associations between each qualitative staining score and FIGO grade. The associations between qualitative staining in the epithelial lining and the connective tissue were not significantly associated with FIGO grade. These analyses considered 12 samples available for analysis. The association between the qualitative staining level of the myometrium is statistically associated with FIGO grade (p=0.022, Wilcoxon rank sum test; not accounting for multiple hypothesis tests). Overall, the data supports the assertion that qualitative staining level of the myometrium is associated with FIGO grade.

[0103] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A method for treating an endometrial cancer in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a formulation comprising:(a) a cannabidiol (CBD), or a salt thereof;(b) a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof;(c) a cancer therapeutic; and(d) an excipient, a carrier, a diluent, or any combination thereof.

2. The method of claim 1, wherein the endometrial cancer comprises an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof.

3. The method of claim 1, wherein the endometrial cancer comprises an endometrial adenocarcinoma.

4. The method of claim 1, wherein the endometrial cancer comprises a clear cell carcinoma.

5. The method of claim 1, wherein the terpene or the salt thereof comprises a P-myrcene, a P-caryophyllene, an ocimene, an a-pinene, an a-humulene, a linalool, a p-cymene, a camphene, a cis-nerolidol, a terpinolene, an isopulegol, a caryophyllene oxide, a 6-limonene, a geraniol, a guaiol, a-bisabolol, a 3-carene, a P-pinene, a y-terpinene, a salt of any of these, or any combination of the foregoing.

6. The method of claim 1, wherein the flavonoid or the salt thereof comprises a naringenin, a naringin, a blumeatin, a butin, an eriodictyol, a hesperetin, a hesperidin, a homoeriodictyol, an isosakuranetin, a pinocembrin, a poncirin, a sakuranetin, a sakuranin, a sterubin, a pinostrobin, a salt of any of these, or any combination of the foregoing.

7. The method of claim 1, wherein the cancer therapeutic comprises a chemotherapy, an non-steroidal anti-inflammatory (NS AID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and / or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, a hormone therapy, a hyperthermiatherapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, or any combination thereof.

8. The method of claim 7, wherein the chemotherapy comprises a 5-fluorouracil, a temozolamide, a 6-mercaptopurine, an azacitidine, a capecitabine, a cladribine, a clofarabine, a cytarabine, a decitabine, a floxuridine, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nelarabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine / tipiracil, a cabazitaxel, a docetaxel, a nab-paclitaxel, a paclitaxel, a vinblastine, a vincristine, a vincristine liposomal, a vinorelbine, a salt of any of these, or any combination of the foregoing.

9. The method of claim 7, wherein the NSAID comprises an ibuprofen, a naproxen, a diclofenac, a celecoxib, a mefenamic acid, an etoricoxib, an indomethacin, an aspirin, a ketorolac, a diclofenac, a meloxicam, a ketorolac, an esomeprazole, a nabumetone, a indomethacin, a mefenamic acid, a piroxicam, a diclofenac, a diflunisal, a sulindac, a ketoprofen, a tolmetin, a fenoprofen, a salt of any of these, or any combination of the foregoing.

10. The method of claim 7, wherein the platinum analogue comprises an el oxatin, a cisplatin, a carboplatin, an oxaliplatin, a nedaplatin, a lobaplatin, a heptaplatin, a triplatin tetranitrate, a phenathriplatin, a picoplatin, a satraplatin, a salt of any of these, or any combination of the foregoing.

11. The method of claim 7, wherein the tyrosine kinase inhibitor comprises a dasatinib, an imatinib, a gefitinib, an erlotinib, a vemurafenib, a sorafenib, a ponatinib, a nilotinib, a masitinib, an axitinib, a pazopanib, a sunitinib, a salt of any of these, or any combination of the foregoing.

12. The method of claim 7, wherein the anthracycline comprises an adriamycin, a caelyx, a cerubidine, a cytarabine, a daunorubicin, a doxorubicin, an epirubicin, a idarubicin, a mitoxantrone, a pharmorubicin, a valrubicin, a daunorubicin, a cytarabine, a salt of any of these, or any combination of the foregoing.

13. The method of claim 7, wherein the taxane comprises a paclitaxel, a docetaxel, a cabazitaxel, a salt of any of these, or any combination of the foregoing.

14. The method of claim 7, wherein the mTOR and / or AKT targeting therapy comprises a rapamycin, AZD 8055, a sirolimus, a temsirolimus, an everolimus, a ridaforolimus, a deforolimus, an apitolisib, MK-2206, a afuresertib, a KRX-0401, a Honokiol, a Torinl, a PP242,a PP30, a Ku-0063794, a WAY-600, a WYE-687, a WYE-354, an INK128, an AZD8055, an OSI-02, a salt of any of these, or any combination of the foregoing.

15. The method of claim 7, wherein the p53 targeting therapy comprises a RG7112, an idasanutlin, a SAR405838, an alrizomadlin, a MK-8242, a TAS- 102, a talazoparib, a APR-246, a ALT-801, a salt of any of these, or any combination of the foregoing.

16. The method of claim 7, wherein the PARP inhibitor comprises an olaparib, a niraparib, a rucaparib, a talazoparib, a salt of any of these, or any combination of the foregoing.

17. The method of claim 7, wherein the sphingolipid metabolism targeting therapy comprises a cytotoxic retinoid, a fenretinide(4-HPR), a sphingosine kinase inhibitor, a fenretinide, a a-galactosylceramide, a ABC294640, a SKI-II, a sonepcizumab, a FTY720, a tamoxifen, a synthetic ceramide, a salt of any of these, or any combination of the foregoing.

18. The method of claim 7, wherein the hormone therapy comprises a progestin, a progesterone, a salt of any of these, or any combination of the foregoing.

19. The method of claim 7, wherein the immunotherapy comprises a lenvatinib, a bevacizumab, a PD-1 inhibitor, a PDL-1 inhibitor, a CTLA-4 inhibitor, a TIGIT inhibitor, a TF inhibitor, a cytokine, or any combination of the foregoing.

20. The method of claim 1, wherein the (a) the cannabidiol (CBD), or the salt thereof; (b) the terpene, the salt thereof, the flavonoid, the salt thereof or any combination thereof; (c) the cancer therapeutic; and (d) the excipient, the carrier, the diluent, or any combination are in the form of a pharmaceutical formulation in unit dose form.

21. The method of claim 1, wherein the cannabidiol (CBD), or the salt thereof and optionally the terpene, the flavonoid, or both are administered consecutively or concurrently with the cancer therapeutic.

22. The method of claim 1, wherein the administering is performed about: 1 time per day, 2 times per day, 3 times per day, 4 times per day, 5 times per day, or more than 5 times per day.

23. The method of claim 1, wherein the administering is performed for a treatment duration of about: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, or longer than 3 years.

24. The method of claim 1, wherein the subject is diagnosed with the endometrial cancer.

25. The method of claim 24, wherein the diagnosis comprises a physical exam, a medial imagining exam, a biopsy, a blood test, or any combination thereof.

26. A pharmaceutical composition in unit dose form comprising an effective amount of: (a) a cannabidiol (CBD), or a salt thereof;(b) a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof;(c) a cancer therapeutic; and(d) an excipient, a carrier, a diluent, or any combination thereof.

27. A kit comprising the pharmaceutical composition of claim 26 and a container.

28. A method for treating a reproductive cancer in a subject in need thereof comprising administering to the subject a composition comprising:a) a cannabidiol (CBD) or a salt thereof, wherein the CBD or the salt thereof activates a CBD receptor associated to the reproductive cancer in the subject;b) a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; c) a cancer therapeutic; andd) an excipient, a carrier, a diluent, or any combination thereof,wherein the administering of the composition results in the modulation of cancer-associated cell signaling in the subject.

29. The method of claim 28, wherein the administering of the composition produces improved cancer reduction compared to a standard of care treatment for reproductive cancer without administration of the composition.

30. The method of claim 28, wherein the modulation of cancer-associated cell signaling comprises the modulation of immunoexpression.

31. The method of claim 28, wherein the reproductive cancer is an endometrial cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a soft tissue sarcoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, vascular cancer, or any combination thereof.

32. The method of claim 28, wherein the administering comprises nonparenteral administration or parenteral administration.

33. The method of claim 28, wherein the administering of the composition results in the modulation of cancer-associated cell signaling in the reproductive organs.

34. The method of claim 28, wherein the administering of the compositions results in the modulation of cancer-associated cell signaling in the lymphatic pathways and / or lymph nodes.

35. The method of claim 28, wherein the composition is co-administered with at least one more therapy.

36. The method of claim 35, wherein the at least one more therapy comprises a cancer therapy, a chemotherapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, an immune therapy, a non-steroidal anti-inflammatory (NS AID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and / or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, a cannabinoid, or any combination thereof.

37. The method of claim 35, wherein the at least one more therapy targets peroxisome proliferator-activated receptor alpha (PPARa).

38. The method of claim 35, wherein the at least one more therapy does not comprise a cannabinoid.

39. The method of claim 28, wherein the composition is administered in an amount of about 0.0001 g to about 500 g.

40. The method of claim 28, wherein the composition is administered in an amount of about 1 mg to about 5000 mg of an active ingredient in a single dose.

41. The method of claim 35, wherein the at least one more therapy is administered in an amount of about 0.0001 g to about 500 g.

42. The method of claim 35, wherein the at least one more therapy is administered in an amount of about 1 mg to about 5000 mg of an active ingredient in a single dose.

43. The method of claim 28, wherein the method further comprises a physical exam, a medial imagining exam, a biopsy, a blood test, or any standard diagnostic technique.

Images